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The radiation therapy of bladder cancer patients is challenging especially because of 
the changing volume and shape of the bladder. With the on-line adaptive method, it is 
possible to aim the treatment accurately to the bladder, but the use of the method 
demands special features from the treatment unit. 
 
The goal of this Master’s Thesis was to assure the functionality of the new linear 
accelerator Elekta Axesse in Helsinki University Central Hospital (HUCH) and to 
investigate the prospective benefits of the features; volumetric-modulated arc therapy 
(VMAT), cone-beam computed tomography (CBCT) and six degrees of freedom, for 
the treatment of patients with bladder cancer. Furthermore, it was a goal to introduce 
comprehensive instructions for the treatment process, including strategies for 
treatment planning, plan verification, CBCT imaging and patient positioning. 
 
In order to assure the functionality of the treatment unit, phantoms were developed. 
The one constructed around the matrix detector was used for the VMAT plan 
verification process, and the internal organ phantom was generated in order to 
investigate the CBCT imaging and the accuracy of patient positioning. The VMAT 
treatment plans were created using the treatment planning system Monaco. 
 
As a result of the Thesis, the equivalence between the calculated and delivered VMAT 
treatment plans was shown to be in 3 % and 3 mm scales with 95 % of point doses. 
The accuracy and functionality of the CBCT system were shown to work in 0.1 cm 
and 0.1° scales. In addition, new presets were created especially for imaging bladder 
cancer patients with the CBCT. Into the treatment planning system was attached the 
VMAT treatment plan template which is also a part of the created instructions for the 
complete radiation therapy process of patients with bladder cancer. Using the 
instructions, five patients with bladder cancer were treated during the spring 2011. 
 
As a conclusion of the Thesis, the Elekta Axesse linear accelerator makes it possible 
to treat the bladder cancer patients very reliably and accurately with radiation therapy. 
 
Keywords: Radiation therapy, volumetric-modulated arc therapy, cone-beam 
computed tomography, six degrees of freedom and on-line adaptive method. 
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Virtsarakkosyöpää sairastavien potilaiden sädehoito on haasteellista erityisesti 
virtsarakon tilavuuden ja muodon vaihtelun vuoksi. Kuvantaohjatun adaptiivisen 
menetelmän avulla on pystytty kohdistamaan sädehoito tarkasti virtsarakkoon, mutta 
menetelmän käyttäminen vaatii kuitenkin erityisiä ominaisuuksia sädehoitolaitteelta.  
 
Tämän työn tavoitteena oli varmistaa Helsingin yliopistollisen keskussairaalan 
(HYKS) uuden Elekta Axesse sädehoitolaitteen toiminta kliinisessä ympäristössä ja 
tutkia sädehoitolaitteen erityisominaisuuksien; intensiteettimuokatun kaarihoidon, 
kartiokeilatietokonetomografian ja kuusiulotteisen potilasasettelun, etuja virtsa-
rakkosyöpää sairastavien potilaiden sädehoidossa. Hoitojen toteuttamiseksi oli 
tavoitteena esitellä annossuunnittelun, suunnitelmien laadunvarmistamisen, potilaan 
kuvantamisen ja potilasasettelun sisältämä sädehoito-ohje. 
 
Sädehoitolaitteen toiminnan varmistamiseksi kehitettiin testikohteita, joista matriisi-
ilmaisimen ympärille kehitettyä systeemiä käytettiin annosjakaumien laadun-
varmistukseen ja kliinisesti yhteensopivaa testikohdetta kuvantamisen ja 
potilasasettelun tarkkuuden selvittämiseen. Intensiteettimuokattujen kaarihoito-
suunnitelmien kehittämiseen käytettiin Monaco hoidonsuunnittelujärjestelmää.  
 
Tämän työn tuloksena laskettujen ja toteutuneiden intensiteettimuokattujen 
kaarihoitosuunnitelmien välinen vastaavuus osoitettiin olevan 3 %:n ja 3 mm:n sisällä 
95 %:ssa mittauspisteistä. Kuvauslaitteen ja potilasasettelun toiminta varmistettiin 0,1 
cm:n ja 0,1°:n tarkkuudella. Laitteeseen luotiin erityisesti virtsarakkosyöpää 
sairastavien potilaiden kuvantamiseen sopivia asetuksia. Hoidonsuunnittelu-
järjestelmään lisättiin kaarihoitosuunnitelmapohja, joka on myös osa virtarakkosyöpää 
sairastavien potilaiden hoitamiseksi kehitettyä sädehoito-ohjetta. Ohjeen perusteella 
hoidettiin viisi potilasta HYKS:ssa kevään 2011 aikana. 
 
Tämän työn perusteella voidaan todeta, että Elekta Axesse sädehoitolaite mahdollistaa 
virtsarakkosyöpää sairastavien potilaiden hoitamisen erittäin luotettavasti ja tarkasti. 
 
Avainsanat: Sädehoito, kuvantaohjattu adaptiivinen menetelmä, intensiteettimuokattu 
kaarihoito, kartiokeilatietokonetomografia ja kuusiulotteinen potilasasettelu. 
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Lists of symbols and abbreviations 
 
List of symbols 
 
Dm  measured absorbed dose using matrix detector 
Dw   absorbed dose in water 
J100   percentage dose of maximum dose at depth of 100 mm 
J100/ 200 ionization ratio between depths 100 and 200 mm 
KAcc measurement accuracy of matrix detector 
KC   calibration factor for measured dose distributions by the created  
  verification system 
KDR relative difference between daily and reference dose rate 
Km  factor for calibrating the ionization chambers of matrix to the 
chamber of absolute dosimetry 
kp, t  correction factor for the ionization chamber’s calibration factor’s 
pressure and temperature dependence 
KR  relative factor between a measured or calculated point dose and the  
  measured point dose with gantry angle 0° 
kr   recombination coefficient 
KT   factor for eliminating the effect of attenuation by the treatment table 
Kγ  factor for correcting the dependence of measuring angle of the 
chambers of the matrix 
M   charge measured by ionization chamber 
m   readout of the electrometer 
MD measured absorbed dose using matrix in different investigations 
ND, w, Q calibration factor for ionization chamber 
TM  traversed distance of radiation in matter to the measuring point  
α gantry angle 
βArc size of an arc 
βT size of the sector of an arc where attenuation by the treatment table 
need to be considered 
 
List of abbreviations 
 
CBCT Cone-beam Computed Tomography 
CT  Computed Tomography 
DVH Dose Volume Histogram 
EUD Equivalent Uniform Dose 
Gy  Gray 
HUCH Helsinki University Central Hospital 
ICRU International Commission on Radiation Units and Measurements 
IMRT Intensity Modulated Radiation Therapy 
MLC Multileaf Collimator 
MV Megavolts 
OBI On-Board Imager 
PDD Percentage Depth Dose 
PMMA Polymethyl Methacrylate 
PTV Planning Target Volume 
VMAT Volumetric-modulated Arc Therapy 
 
1 Introduction 
 
The treatment of patients with bladder cancer using radiation therapy involves peculiar 
challenges. Pivotal problems are caused by organ motion in the pelvic area and the 
varying volume of the bladder. Furthermore, the vicinity of organs at risk and the 
incontinence of the patients set some constraints on treatment. By observing these 
challenges the on-line adaptive method for basis of the radiation therapy of patients 
with bladder cancer has been developed. The method is based on image-guided 
radiation therapy, in which a three-dimensional image of the patient positioned on the 
treatment table is required before delivery of the treatment.  
 
The challenges of radiation therapy for bladder cancer patients and the use of the on-
line adaptive method establish high requirements for the treatment unit. A linear 
accelerator should be equipped, at least, with a high level on-board imaging system and 
be able to deliverer dynamical fields. With recently installed linear accelerator Elekta 
Axesse (Elekta Instrument AB, Sweden) at the Department of Oncology of Helsinki 
University Central Hospital (HUCH) it is possible to face the requirements. The linear 
accelerator is equipped with cone-beam computed tomography (CBCT) device, 
treatment table with six degrees of freedom and it is capable for volumetric-modulated 
arc therapy (VMAT).  
 
In order to bring a new treatment unit into clinical use, it is essential, that verifications 
between planned and delivered dose distributions are done exactly. Using the Elekta 
Axesse linear accelerator, the plan verification process encounters new challenges 
caused by the rotational character of VMAT. For this purpose it is crucial to create a 
reliable verification system before starting treatment of patients. In addition, clinical 
verification of the matching accuracy of the CBCT system with the planning computed 
tomography (CT) image and the co-operation between the CBCT system and the 
mobile treatment table has to be assured. Also the delivered doses of the CBCT images 
have to be determined. 
 
VMAT treatments require special properties also from the treatment planning system. 
At the same time, with the new linear accelerator, also a VMAT capable Monaco 
treatment planning system (Elekta CMS Software, Germany) was installed. The use of 
a new planning system with new kinds of treatment methods signifies challenges to 
identify suitable ways to work with the system to obtain feasible solutions for 
treatment. It is important for the clinic to create a gold standard, i.e. a template, for 
specific patient cases in treatment planning. In the case of patients with bladder cancer, 
it is desirable to create a reliable template for the whole treatment process including 
also a strategy for accurate patient positioning. 
 
 
2 Theoretical Backgrounds and the Goals of the Project 
 
2.1 Photons in radiation therapy 
 
The properties of electromagnetic radiation such as attenuation, absorption and 
interactions in tissues provide the basis for dose calculation in radiation therapy. 
Between photons and absorbing, materials encounter processes of interactions that have 
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an effect on the attenuation of radiation. The energy of the radiation and the properties 
of the material have essential influences on processes, which do not border on to the 
interactions of primary photons, but also there are following secondary- , tertiary, etc 
processes. With the photon energies used in radiation therapy, the photons lose their 
energy to electrons most of all caused by three different interactions. First, by Compton 
scattering, in which a photon loses some of its energy in interaction with an atomic 
electron. A scattered photon moves on as a photon with a longer wavelength than 
before and the emitted electron loses its energy in the following interactions in matter. 
Another significant mechanism is pair production. In this process a photon interacts 
strongly with the electromagnetic field of an atomic nucleus and gives up all of its 
energy in the process of creating a pair consisting of a negative and a positive electron. 
These commonly short-lived positrons generate photons around them while absorbing 
in matter. Third, a noteworthy phenomenon is the photoelectric effect. In this process 
the entire energy of a photon is absorbed by an atom in an interaction, where the energy 
is re-transferred to ejected orbital electrons. Throughout among these processes is 
formed absorbed dose in matter. It is defined as the energy absorption of one Joule of 
ionizing radiation imparted by one kilogram of matter, and it is announced in units of 
Gray (Gy). [1][2] 
 
In addition to just knowing the phenomena of ionizing radiation in matter, it is crucial 
to be able to determine how the overall dose is distributed in practise. This can be 
examined using dose measurements and analyses of different dose graphs. For example 
by percentage depth doses (PDD), which describe the percentage doses in matter 
compared to the dose at maximum point with a certain field size and energy. By PDDs, 
for example, a ratio between doses at depths of 100 and 200 millimetres, i.e. ionization 
ratio, can be determined. It is also important to investigate dose distributions at a 
certain depth in matter outside the middle axis. This is possible by so-called profiles, 
which can be normalized in two ways depending on what it is desired to investigate. 
The first way is to normalize many profiles of a field to the value at the depth of 
maximum dose. In this case it is possible to investigate the attenuation of a field as a 
function of depth. Normalizing can also be done to the dose at the middle axis of each 
depth. With this off-axis-ratio it is possible to investigate how dose is distributed 
compared to the middle axis. It can be investigated even more visibly with so-called 
decrement graphs, which are formed by merging the points at which there are the same 
relative doses. Significant graphs in dose distribution analysis are also isodoses, which 
can be constructed when dose distribution is normalized into a specific point dose. All 
the other point doses in the investigated area are compared to the specified point dose. 
The ones with the same relative doses are merged to form a graph; isodose. [1][2] 
 
By the physical properties of ionizing radiation and the information analyzed by 
measurements, it is possible to change photon flux into overall dose at every point of 
the irradiated area to form dose distributions. These can be calculated nowadays by 
treatment planning systems’ calculation algorithms, in which all possible kinds of fields 
and plans should be modelled. In the traditional external beam photon radiation therapy 
the dose calculation and delivery of the radiation beams are based on static fields. In 
general, the static fields have almost uniform intensity across a field. Occasionally, for 
example wedges have been used in order to change beam intensity profiles to meet the 
goals of a composite plan. This process is called intensity modulation, which is 
nowadays possible to perform with variously shaped computer-controlled intensity 
modulation systems such as dynamic multileaf collimators (MLCs). Using dynamic 
 3
MLC, several treatment fields with nonuniform fluence can be optimized by a proper 
treatment planning system to form composite dose distribution into the target volume. 
By using this intensity modulated radiation therapy (IMRT), also the dose calculation 
works in a different way. By so-called inverse planning the treatment goals, criteria and 
beam directions are inserted into the software by the user. Using the information, the 
treatment planning system tries to calculate optimal fluence profiles for each field by 
creating suitable movements for the dynamic MLC. The resulting composite dose 
distributions should include a high dose in the target volume and an acceptably low 
dose in the surrounding healthy tissues. Dose distributions can have irregular shapes, 
for example concave ones, which can be observed by isodoses in three dimensions. In 
the trajectory of the IMRT technique the amount of dynamical features have increased 
by adding a rotational property of the gantry while beam is on. Generally, this method 
is called intensity modulated arc therapy. From it has evolved volumetric-modulated 
arc therapy, in which also simultaneous variations of dose rate and gantry speed are 
allowed. [1][2][3][4][5][6] 
 
 
2.2 Radiation therapy as a treatment for patients with bladder cancer 
 
Traditionally, the standard treatment for patients with muscle-invasive urinary bladder 
cancer is radical cystectomy. However, some patients have inoperable tumours or their 
medical conditions make them unfit to undergo the cystectomy. For these patients 
radiation therapy is an effective treatment. Conventional radiation therapy technique for 
this group of patients includes one planning target volume (PTV) designed by one 
treatment planning CT image. In order to take into account the maximum changes of 
the bladder’s shape, size and position, the margins of the PTV have had to be designed 
wide enough to ensure sufficient dose coverage. All of the treatments, i.e. fractions, are 
realized by the one and only treatment plan. This method implies irradiation of large 
volumes of healthy tissues especially by the fractions during which the bladder volume 
is relatively small, i.e. when the bladder is empty. [7][8][9] 
 
The development of the technologies and methods of image-guided radiation therapy 
have made it possible to identify and correct problems arising from inter- and 
intrafractional variations in patient setup and anatomy, including the shapes and 
volumes of the treatment target, organs at risk and the surrounding normal tissues. By 
these improvements the on-line adaptive method has been introduced for the basis of 
the radiation therapy treatment of bladder cancer patients. With this method constant 
changes in bladder volume and positions of internal organs in the pelvic area have been 
taken into consideration by the bladder localization before every fraction and also by 
having several treatment plans created for different PTVs. Using four CT images taken 
within an hour after urinating, four different target volumes can be planned. Before 
every fraction the prevailing situation of the bladder is tracked down by a CBCT image. 
The position and shape of the bladder is compared to the four contoured bladder shapes 
by the four planning CT images. The plan created by the bladder shape, which is most 
equivalent to the daily bladder shape, is then treated. This method can reduce the dose 
to the organs at risk, while maintaining the dose coverage of the target volume at a 
similar level, compared to the conventional treatment technique. [2][7] 
 
In radiation therapy of bladder cancer patients in HUCH the on-line adaptive method 
has been in use since 2009. The treatment offered in 2009 and 2010 was realized using 
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Varian Clinac iX (Varian Medical Systems Inc., Palo Alto, CA, USA) linear 
accelerator, which is equipped with the On-Board Imager (OBI) CBCT system. In 
treatment planning the IMRT technique has been used with seven treatment fields with 
6 and 15 MV photon energies. The treatment planning process has been realized using 
the treatment planning system Eclipse (Varian Medical Systems Inc., Palo Alto, CA, 
USA) with kernel based pencil beam convolution calculation algorithm. The objectives 
set by International Commission on Radiation Units and Measurements (ICRU) in 
report 50 have been used as the goals for target dose. The planned target doses have 
been between 55.8 and 65 Gy, for which one of the limiting factors has been the 
amount of radiation that the bowels are exposed to. [7] 
 
 
2.3 The Goals of the Project 
 
The comprehensive goal of the project is to introduce instructions for suitable working 
process for the radiation therapy of patients with bladder cancer in HUCH by utilizing 
the new Elekta Axesse linear accelerator with its features. In order to achieve this goal, 
there are many partial issues, which have to be investigated. By introducing strategies 
individually for all the parts of the working process, the comprehensive working 
strategy can be constituted. 
 
Before beginning to plan patient treatments the equivalence between the VMAT 
treatment plans created by the Monaco treatment planning system and delivered by the 
Elekta Axesse linear accelerator have to be configured. To achieve this goal it is 
relevant to create a reliable verification system. For the treatment of patients with 
bladder cancer also the accuracy of image guidance has to be ensured. So, it is also a 
goal to assure the performance of the CBCT system by image quality, automatic 
matching capabilities and precise patient repositioning. Furthermore, it is an aim to find 
such combinations of parameters for CBCT imaging, which would make it possible to 
perform images with good enough image quality with as low irradiation as possible. 
 
After achieving the goals concerning the operations of the equipment, the concentration 
of the investigations can be focused on the use of the equipment. For treatment 
planning it is a goal to find suitable settings and parameters, which would form the 
basis of a workable template for VMAT treatment planning of patients with bladder 
cancer. Also introduction of a suitable strategy for performance of the CBCT imaging 
and patient positioning is set as a target. In the end, by all the reached goals, 
comprehensive instructions for the radiation therapy of bladder cancer patients should 
be introduced including strategies for VMAT treatment planning, plan verification and 
patient positioning. 
 
 
3 Basics of the Equipment Used in the Project 
 
3.1 Linear accelerator Elekta Axesse 
 
Elekta Axesse is a linear accelerator with modern features and equipment for radiation 
therapy. The one in HUCH was installed recently in October 2010. The accelerator 
includes three photon energies, which can be delivered by varying dose rates even 
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while the gantry is rotating. The gantry can be rotated a complete 360° circle by starting 
from gantry angle of 180° with a maximum speed of 360° in a minute. Treatment plans 
can be realized in the clock-wise direction of rotation. The fields can be shaped by 
dynamic MLC, which includes a set of 40 leaf pairs, in which each leaf is four 
millimetres wide. The leaves are able to move with a speed of 2.5 centimetres per 
second even while the gantry is rotating and the beam is on. The dose rate variations 
can be irradiated up to 600 monitor units per minute with the energy of 6 megavolts 
(MV). These features of the linear accelerator make it possible to use VMAT in 
treatment planning. In VMAT treatment planning the used arc is split into segments, 
which also represent the control points of the treatment. An example of the movement 
of the dynamic MLC during a segment is shown in image 1. The realization of a 
VMAT treatment plan is controlled by the treatment unit’s computer by the instructions 
of the plan made by a treatment planning system. The computer of the treatment unit 
controls the progression of a plan by monitoring the treated monitor units, dose rate 
variations and the actual movements of the leaves as well as rotating the gantry during 
the segments. [2][3][4][5][10] 
 
        
 
Image 1: Function of dynamic MLC in VMAT treatment plans. On the left the start position, and on the 
right the end position, of dynamic MLC in a segment with 4° gantry rotation and 9.5 monitor units. 
 
The linear accelerator, which is shown in image 2, is equipped with two kinds of on-
board imaging systems. With these systems it is possible to obtain on-line information 
about patient positioning, and so improve the accuracy of delivery of the treatment to 
its target volumes. A megavoltage electronic portal imaging device provides planar 
imaging using the accelerator’s treatment photon energies. A flat-panel image detector 
is positioned opposite the source of megavoltage radiation. Even though the detector is 
a modern matrix system with amorphous silicon photodiode detectors, the image 
quality is relatively poor with megavoltage class photon energies. Because of this, the 
linear accelerator is also equipped with an on-board kilovoltage imaging system to 
produce high quality three-dimensional volumetric images. This CBCT system called 
Xvi includes its own x-ray tube positioned 90° clock-wise from the gantry and flat 
panel area detectors mounted opposite the x-ray tube. The CBCT system performs 
numerous planar projection images from multiple directions as the gantry rotates at 
least 180°. With these radiographs the software of the CBCT system constructs a three-
dimensional volumetric image using a filtered back-projection algorithm. There are a 
number of pre-programmed presets for imaging in Xvi. However, some of the 
parameters can be manually adjusted by a user to have an effect, among other things, on 
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image quality and delivered dose. The CBCT images, also denoted localization images, 
can be matched with a reference image, which is a planning CT image, manually or by 
one of the matching algorithms of the software. These algorithms are designed to 
concentrate on recognizing differences in electron densities within a specified range 
between tissues. With the information obtained from the matching process, a patient 
can be re-positioned if necessary. [2][10][11] 
 
 
 
Image 2: Elekta Axesse in HUCH. The gantry is set at a position of 0°. Opposite to the gantry is the flat-
image detector for megavoltage radiation. The x-ray tube is on the right in the image and the detector for 
kilovoltage radiation is opposite to it. In the sealing is an infrared stereo tracking camera and on the 
treatment table is attached a frame of passive reflectors. On the wall on the very left in the image are the 
lasers for longitudinal and vertical patient positioning.
 
To get the full advantage out of the three-dimensional image of CBCT for patient 
positioning, the treatment unit is equipped with a treatment table system called 
Hexapod. The carbon fibre treatment table is positioned on top of two motorized 
movement units. Hexapod is able to be moved in all six degrees of freedom, which 
makes it possible to correct both translational and rotational positioning errors as shown 
in image 3. In the translational directions the range of movement accuracies are 0.1 mm 
in the maximum range of translations +/- 3 cm, +/- 3 cm and +/- 4 cm in x-, y-, and z-
directions, respectively. In the rotational directions the range of movement accuracies 
are 0.1° in the maximum range of +/- 3° in all directions. The table position is 
computer-controlled via the iGuide software that the treatment table system’s computer 
is running. The table is guided by an infrared stereo tracking camera installed in the 
sealing of the treatment room. The camera detects the positions of five passive 
reflectors, which are positioned on a frame attached to the treatment table. 
[10][11][12][13] 
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Image 3: Coordinate system of Elekta Axesse [10]. In the coordinate system the lateral direction is set as 
x, longitudinal as y and vertical as z.  
 
 
3.2 Treatment planning system Monaco 
 
Due to many degrees of freedom in VMAT treatment planning, the optimization 
process is computationally challenging. The treatment planning system needs to be able 
to calculate optimal dose distributions by considering the limitations of the accelerator 
and by trying to solve dose delivery challenges by using multiple dynamic property of 
the accelerator at the same time. These push calculation algorithms to their limits and 
raise calculation times even compared to conventional IMRT. Inverse plan optimization 
in IMRT is traditionally performed by dose volume histogram (DVH) optimization 
objectives. This method lets the user set dose levels for different contoured volumes of 
anatomical targets and organs of interest. The nonlinear responses of tumours or organs 
to radiation dose are not, however, adequately represented. In cases where a small 
number of voxels in a tumour volume receive a very low dose, it would not have any 
significant effect on the result of the plan. However, as a result the tumour control 
probability would be greatly diminished. This issue is relevant especially with arbitrary 
inhomogeneous dose distributions, which are reconstructed by inverse planning. The 
losses of tumour control and the capability of an organ to survive, if some parts of it 
lose capability to function, are considered in biological optimization. The biological 
information can be supplied in terms of tumour or normal tissue complication 
probability models or equivalent uniform doses (EUDs). The EUD of the target tissue is 
defined as the biologically equivalent dose that, if given uniformly, will lead to the 
same cell kill in the tumour volume as the actual nonuniform dose distribution. 
[3][4][5][6][14] 
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The Monaco treatment planning system is a tool, which utilizes not only the physical 
effects of radiation, but also EUDs and the biological properties of the tissues. The user 
has a possibility to set the cell sensitivity of Poisson’s cell kill model. Organs at risk 
can be set as serial or parallel constraints depending of the properties of the tissue to 
function after a certain level of exposed radiation into them. The user is able to 
influence the amount of volume of a structure, which can be sacrificed, and also affect 
the strengths of the limits of the constraints. The system uses a two-step VMAT 
optimization process. In the first phase of optimization the treatment planning system 
creates the user specified arc by segments, which operate also as control points at the 
treatment unit’s computer during treatment. Then the calculation algorithm of the first 
phase optimizes the fluence distributions for the segments. At this phase the fluence 
distribution is calculated by the pencil beam convolution algorithm, which considers 
dose to be produced by the sum of narrow cylindrically symmetry beams. The dose at a 
point in the patient is calculated by summing the calculated dose distribution of all 
pencil beams to the examination point. Because the algorithm is kernel-based two-
dimensional method, the accuracy is limited especially in the presence of 
heterogeneities, but the calculation times are relatively short. Inside the limits of the 
accelerator, the user may influence, for example, the dose rate, minimum dose per 
segment and calculation grid spacing by changing these parameters in the optimization 
properties window of the software. By influencing these, the user is able to optimize the 
best possible solution by making compromises, for instance, between plan quality and 
treatment time [4]. In the second calculation phase, the treatment planning system takes 
into account the deliverability of the accelerator, which is limited, for example, by 
restrictions on MLC and gantry movements, as number one in priority. The optimal 
field shapes are then generated in order to produce as smooth composite dose delivery 
as possible [5]. As a result, plan quality might be adversely affected in comparison to 
the fluence distribution calculated in the first phase. The second phase calculation can 
be done by a voxel based Monte Carlo method which enables more accurate dose 
distribution calculation than the analytical algorithms. The Monte Carlo method 
calculates the number of electrons created in each voxel by the primary photon beam 
and particles created in interactions. The final calculated dose distribution is formed by 
the most presumable distribution of the absorbed dose. The user may affect the 
calculation accuracy and time by modifying some parameters of calculation properties 
like the Monte Carlo variance and grid spacing. [1][2][3][15][16] 
 
 
3.3 Dosimetric equipment 
 
The ionization chambers are standard detectors of dosimetry in radiation therapy. The 
basic theory of the chambers is based on the cavity theorem of Bragg-Gray. The 
chambers are constructed by a cavity of gas, containing two electrodes with different 
potentials. The electrodes capture the generated charge carriers. Ionization is defined by 
the relative current, which is determined by an electrometer. Ionization chambers of 
absolute dosimetry are calibrated in secondary laboratories by national radiation 
authorities under a known field of radiation usually with 60Co-calibration. The 
calibration is based on determined absorbed dose in water by international primary 
laboratories in so-called standard conditions of pressure 101.3 kPa and temperature 20 
°C. In use of ionization chambers it is essential to consider many issues concerning 
either the chamber or the measurement circumstances. These are, for example, the 
correction factor of interference, a correction factor for a chamber’s calibration factor’s 
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pressure and temperature dependence, as well as a recombination coefficient. 
Recombination of ions and electrons is caused by pulsation in the linear accelerator’s 
radiation during high instantaneous velocities of dose-rate. By a recombination 
coefficient the finite of a chamber’s collecting-efficiency is taken into account. So, by 
taking into account these issues and by knowing ionization ratio and the relativity of the 
irradiated dose and electrometer, it is possible to calculate absolute dose using the 
equation 
 
  Dw = ND, w, Q · m · kp, t · kr                            (1)
   
where Dw is the absolute dose of photon energy at the measuring point of a chamber,      
ND, w, Q is calibration factor, m is the readout of an electrometer, kr is the recombination 
coefficient and kp, t is a correction factor for the chamber’s calibration factor’s pressure 
and temperature dependence. This correction factor kp, t for daily environmental 
conditions can be calculated by equation 
 
  kp, t = (T / T0) · (p0 / p)                                         (2) 
 
where T is measured temperature in kelvins, T0 is 293.2 K, p is measured pressure in 
pascals and p0 is 101.3 kPa. [1][2][17] 
 
One of the basic parts of quality control equipment in radiation therapy is a water 
phantom, which includes a cubic shape water tank with a capacity of about 200 litres. 
This system can be positioned in the treatment room under the gantry when the gantry 
angle is set as 0°. In the water tank there is a holder for an ionization chamber, which 
can be moved in three dimensions. With this moving ionization chamber it is possible 
to measure, for instance, point doses, percentage depth doses and profiles. On the top 
corner of a water phantom, there is also a holder for a reference chamber which 
monitors the dose rate. The measured data is recorded and analyzed by the equipment’s 
software. [1][7][18] 
 
In order to measure dose distributions in a two-dimensional level, ionization chamber 
arrays can be used. These so-called matrix detectors have a number of separate 
ionization chambers positioned usually into a shape of a square. The ionization 
chambers of these devices are open to outside air, and they are calibrated in certain air 
pressure and temperature conditions usually with 60Co-calibration. The devices are 
planned to measure radiation entering the device from towards, either by positioning 
device on the treatment table and setting the gantry angle at 0°, or by attaching the 
device to the head of the gantry by a fixation device. The measured data is evaluated by 
algorithms of the device’s software. The measured dose distribution is then available 
for analyses and comparisons with calculated dose distributions. [19][20] 
 
Film dosimetry is a common field in two-dimensional relative dosimetry. A pivotal 
assumption in film dosimetry is that the dose to the film is reflected in the resulting 
optical density of the film. These radiochromic films have an ability to produce a 
permanent visible colour change upon irradiation. By the polymerisation process, in 
which energy is transferred from an energetic photon to a colourless photo monomer 
molecule, and chemical changes, the image formation of a measured dose distribution 
occurs. To actually get the dose distribution available for analysis, the film is measured 
by special scanners called transmission densiometers. Even though the conventional 
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challenges in film dosimetry caused by the accuracy of densiometers, sensitivity of the 
films to ultraviolet radiation and the sensitivity of the relationship between dose and 
optical density, the film dosimeters have a high spatial resolution and relatively low 
energy spectral sensitivity. [21][22] 
 
 
4 Methods, Materials, Measurements and Calculations 
 
4.1 Verification system for VMAT treatment plans 
 
One of the most crucial issues in the process of radiation therapy is the equivalence 
between treatment planning and the actual delivery of the treatment. The calculated 
dose distributions in units of Gray should be delivered by a relative amount of monitor 
units, which describe the sensitivity of the linear accelerator’s interior ionization 
chamber i.e. monitor chamber. The grounds of the automatic calculations of the relative 
monitor units by treatment planning systems are in the number of measurements done 
with each linear accelerator. With these results, the accelerator-specific calibration 
factor is determined for all of the energies. It is necessary to establish, that the adjusted 
treatment planning system works the way it should be by creating dose distributions, 
which linear accelerators are able to generate. This verification is essential to realize 
before starting patient treatment. Dose distribution measurements are also important in 
the long term to assure that the calibration factors remain updated. [1][2][23] 
 
The verification procedures for treatment plans with static fields are mostly done by 
measuring created dose distributions by positioning the measuring device, like matrix, 
straight towards the gantry [19]. The property of VMAT treatment plans with a moving 
gantry while radiation is on creates totally new challenges for the treatment plan 
verification process. It is possible to realize plan verifications of VMAT treatment plans 
by creating quality assurance plans in which movements of the gantry are inhibited, and 
so the radiation beams are delivered only by a static gantry angle 0° [19]. However, this 
eliminates obviously one significant part of realization of a VMAT treatment plan, and 
means that it is neither possible to test or consider the functionality of moving gantry 
and its effect on dose distribution. 
 
It would be desirable to be able to realize VMAT treatment plan verifications also with 
rotation of the gantry. This gives a boost to start investigations of the possibility to 
create a suitable and reliable way of measuring dose distributions by matrix with a 
rotating gantry of 360°. This creates two additional challenges, which need to be 
considered in measurements: first, the measuring accuracy of the matrix relative to the 
direction of radiation, and; second, the effect of attenuation by the treatment table. To 
investigate these issues, a reproducible system should be created, which could work 
also as a phantom for VMAT treatment plan verification. 
 
In order to create a verification system there is a need of a specified measuring device. 
For this purpose, 2D-Array seven29 (PTW Freiburg GmbH, Germany) is decent. It is a 
two-dimensional matrix detector with 729 ionization chambers, which are arranged to 
make a regular matrix of 27 · 27 chambers [19]. The sizes of the chambers are 5 · 5 · 5 
mm3, the gaps between the chambers are 5 mm and the material around the chambers is 
polymethyl methacrylate (PMMA), which makes a 5 mm thick layer on top of the 
chambers and a 10 mm thick layer underneath the chambers [19][23][24]. To build a 
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system around the matrix there should be a suitable material with known properties to 
set around it. For this case the properties of water-equivalent RW3 material, so-called 
solid water, are reasonable [25]. Seven 1 cm thick slabs with a covering area of 30 · 30 
cm are placed both on top and under the matrix. Construction of the created system is 
shown in image 4. To make this system an efficient and reliable measuring tool for 
treatment plan verification, there are a couple of things that need to be investigated. 
Besides the before-mentioned dependence of the measuring angle of the matrix and the 
effect of attenuation by the treatment table, there should be evaluated repeatability 
accuracy of the matrix, the effect of changing environmental conditions and the dose-
rate of the accelerator. Also to be able to compare the measured dose distribution with 
the calculated one, it is necessary to calibrate the matrix with the treatment planning 
system. By finding factors which calibrate these issues out, and so make measured and 
calculated dose distributions relative to each other, it is possible to realize the 
configurations of the introduction of energies and also the quality assurance 
measurements of VMAT treatment plans. 
 
  
 
Image 4: Cross section of the created VMAT treatment plan verification system positioned on the 
treatment table. 
 
 
4.1.1 Calibration factor for measured dose distributions 
 
An issue that needs to be considered always with a matrix, or with whatever measuring 
device, is the reliability and accuracy of the measuring device. By solving the repetitive 
accuracy it is possible to analyze the results of other measurements within a certain 
tolerance. Before all the measurements, also changing environmental conditions need to 
be considered. Air pressure and temperature are measured and inserted to the matrix’s 
software called VeriSoft, which automatically correlates the measurement device for 
daily conditions by calculating a calibration factor for measured doses [19]. The daily 
dose rate of the linear accelerator is taken into account always before investigations by 
measurements with the energy, that is going to be used in measurements by radiating 
100 monitor units with a field size of 10.4 · 10.4 cm by a gantry angle of 0° and source 
to detector distance of 100 cm to the isocenter of the matrix system. The positioning of 
the system for these measurements is shown in image 5. If the measured value is more 
different than the repetition accuracy of the matrix from the dose at the measuring day 
of the absolute measurements, a correlation needs to be done before any relative 
measurements are realized. Comparable measurements of absolute dosimetry to 
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measurements done by the matrix in similar circumstances are done also because the 
treatment planning system is configured by absolute dosimetry measurements. With 
this calibration factor it is possible to compare the calculated and measured dose 
distributions. As mentioned in the previous chapter it is also essential to define the 
correlation factor for measuring the angle dependence of the matrix and the effect of 
attenuation by the treatment table. With these three factors it is possible to calculate a 
combined correlation factor for measured dose distribution to be comparable against the 
calculated one using the following equation 
 
  KC = Km · KT · Kγ                       (3) 
 
where KC is the correlation factor for measured dose distribution to compare with the 
calculated one with the used arc, Km is the calibration factor to make the matrix 
comparable with absolute dosimetry, KT is correlation factor for elimination of the 
effect of attenuation by the treatment table and Kγ is the correlation factor of the 
measuring angle dependence. 
 
 
 
Image 5: The created VMAT treatment plan verification system positioned on the treatment table. 
 
 
Calibration of chambers of the matrix to the chamber of absolute measurements, 
repetitive measuring accuracy of chambers of the matrix and observation of daily 
dose rate 
 
Determination of the calibration factor to make measurements done by the matrix 
comparable with absolute dosimetry is accomplished by comparing results of 
consecutive measurements of the matrix and by a calibrated ion chamber in similar 
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circumstances with photon energies of 6 and 10 MV. The used ionization chamber is 
called Farmer NE 2571 (serial number 1840) and the used electrometer is called 
dosimeter NE Farmer 2579/1 [2].  The ionization chamber is positioned into a water 
phantom called Blue Phantom2 with Omni-Pro-Accept software (IBA Dosimetry 
GmbH, Germany) [18]. Before the measurements air pressure and temperature of water 
are measured and a correction factor for the chamber’s calibration factor’s dependence 
on daily conditions is calculated by equation 2. Then percentage depth doses with both 
energies are measured. From the recorded data ionization ratios between depths 100 
and 200 mm, and a percentage dose of maximum dose at depth of 100 mm are 
collected. Using the ionization ratio a daily calibration factor for the ionization chamber 
is checked from the calibration certificate [26]. Then the absolute measurements are 
done according to national guidelines of quality controlling [27]. The ionization 
chamber is set at 10 cm deep, which means that the measuring point is at a depth of 9.7 
cm. Reference chamber is set at the corner of the 10.4 · 10.4 cm field, source to skin 
distance is set as 100 cm and the output of the linear accelerator is set to 300 monitor 
units. Measurements are repeated three times. Measured maximum dose per 100 
monitor units can be calculated using the equation 
 
  Dw, max = ND, w, Q · m · kp, t · kr · (1/J100) · (1/3)                                    (4) 
 
where Dw, max is the absorbed dose in water at the maximum point, ND, w, Q is the 
calibration factor, m is the readout of the electrometer, kp, t is a correction factor for the 
pressure and temperature dependence of the chamber’s calibration factor, kr is the 
recombination coefficient and J100 is a percentage dose of the maximum dose at a depth 
of 100 mm. With Dw, max it is possible to estimate the daily dose rate of the accelerator 
because the accelerator is adjusted to produce dose of 1.000 Gy at the point of Dw, max 
by 100 monitor units. Using equation 4 without dividing terms with a value of J100, it is 
possible to calculate the dose in water at a depth of 10 cm. Next, the matrix is set on the 
treatment table. Seven centimetres thick layer of solid water slabs is set underneath and 
a 9.2 cm layer on top of the matrix. So, the measuring point of the middle chamber is 
then set at a depth of 9.7 cm. The source to skin distance is set to 100 cm. Field size and 
monitor units are kept exactly same as in the previous measurements. The 
measurements with the matrix are also repeated three times. The calibration factor to 
make the matrix comparable with absolute dosimetry Km can be calculated using 
equation 
 
  Km = Dw / Dm                       (5) 
 
where Dw is an average of three repeated measured absorbed doses with the absolute 
chamber and Dm is an average of three repeated measured absorbed doses with the 
matrix. [1][2][17] 
 
The matrix is also positioned on the treatment table the way it is in the created 
verification system for VMAT treatment plans. The reference dose for checking the 
daily dose rate and the random error of the chambers of the matrix are evaluated by 
repetitive measurements. The matrix is irradiated by energies of 6 and 10 MV with 100 
monitor units using a gantry angle of 0° and a field size of 10.4 · 10.4 cm. 
Measurements are repeated ten times and each time the measured dose of the middle 
chamber of the matrix is recorded. An average of ten measurements is calculated. The 
average is set as a reference dose for the daily dose rate measurements. Always before 
 14
starting to investigative measurements, the possible effect of the daily dose rate can be 
estimated using equation 
 
  KDR = MDRef / MDd                       (6) 
 
where KDR is the relative difference between the daily dose rate and the reference dose 
rate, MDRef is the measured dose on the day of the absolute measurements and MDd is 
the measured dose on measuring day. If the factor KDR is larger than the measurement 
accuracy of the matrix, the measured absorbed doses are calibrated by the factor KDR. 
The accuracy of repetitive measurements can be estimated using the following equation 
 
  KAcc = ∆MD/ MDr                       (7) 
 
where KAcc is the measurement accuracy of the matrix, ∆MD is an average of ten 
measurements and MDr is the smallest or the largest measured dose. 
 
 
Factor for elimination of the effect of attenuation by the treatment table 
 
Investigation is planned in order to separate the influence of attenuation by the 
treatment table from the measured dose distributions. The investigative measurements 
are started by positioning the created verification system at the isocenter after moving 
the treatment table laterally at zero position and by preparing accelerator system with a 
field size of 10.4 · 10.4 cm and 100 monitor units. Measurements are done with 
energies of 6 and 10 MV. Measurements need to be done with gantry angles, from 
which radiation traverse through the treatment table to the measuring point of the 
middle chamber of the matrix 8.5 cm above the surface of the treatment table. These 
gantry angles are between 110° and 250°. In image 6 is shown the measurement 
situation with a gantry angle of 110°. Because the exact same lateral symmetry of the 
treatment table, it is not necessary to measure effects from both lateral sides. Measuring 
the gantry angles are at intervals of 10°. In order to consider the changing shapes at the 
lateral sides of the table, so that the effects of different parts of the table can be solved, 
measurements are done also with gantry angles of  107.5°, 112.5°, 115° and 125°.  
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Image 6: Starting angle of the investigations into the effect of attenuation by the treatment table. 
 
After measuring the doses with above-mentioned gantry angles, the created system is 
turned upsides down. With this set up the measurements are done with gantry angles, 
which are comparable to the ones used through the treatment table. Then the factor for 
eliminating the effect of attenuation by the treatment table can be calculated by 
equation 
 
  KT, α = MD180° - α / MDα                        (8) 
 
where KT, α is the factor for eliminating the effect of attenuation by the treatment table 
from a particular gantry angle α and MDs are the measured doses with relative gantry 
angles. With the calculated correlation factors a graph is drawn.  
 
From the graph an average factor for eliminating the effect of the table can be 
calculated by extracted factors between 5° steps, which belong in the sector of the arc. 
In order to determine the calibration factor KC of the created verification system, the 
factor KT can be then calculated using equation 
 
  KT = ((K∆(T, α) – 1) · (βT / βArc)) + 1                      (9) 
 
where KT is the factor for eliminating the effect of attenuation by the treatment table for 
the used arc, K∆(T, α) is an average factor to eliminate the effect of attenuation by the 
treatment table, βT is the size of the sector of the arc in which attenuation by the 
treatment table needs to be considered and βArc is the size of the arc. 
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Measurements in order to determine angle dependence for chambers of the matrix  
 
Also the measuring angle dependence of the chambers of the matrix is investigated 
separately. The relation between the gantry angle and the direction of the radiation to 
the middle chamber of the matrix in the created system is shown in image 7. The 
investigations are done by comparing the measured doses by different gantry angles to 
the ones measured by gantry angle 0° with relative amounts of solid water that radiation 
traverses through to the measurement point of the middle chamber of the matrix. The 
length of traversed matter can be calculated by trigonometric function of cosine 
 
  TMα = 7,5 cm / (Cos α)                     (10) 
 
where TMα is the length of traversed matter from a gantry angle of α. These 
calculations are done between steps of 10° from gantry angle 0° to 180°. The calculated 
length of traversed matter is rounded up by a 1 mm scale. The calculated amounts of 
traversed matter are placed on top of the matrix and the measurements are done by 
energy of 6 MV by 100 monitor units and a field size of 10.4 · 10.4 cm. With the results 
of these comparable measurements, and by taking into account the gantry angle 
dependent effect of attenuation by the treatment table, it is possible to calculate a factor 
to calibrate the chambers’ angle dependence out using equation 
 
  Kγ, α = MD0°, TMα / (MDα · KT, α)                    (11) 
 
where Kγ, α is the correction factor for the measured dose with a gantry angle of α, 
MD0°, TMα is the measured dose by a gantry angle of 0° with the length of traversed 
matter from gantry angle α, MDα is the measured dose by gantry angle α and KT, α is the 
factor for eliminating the possible effect of attenuation by the treatment table with 
gantry angle α. With factors Kγ, α a graph is drawn. From the graph it is possible to 
calculate a factor for correcting the dependence of the measuring angle of the chambers 
of the matrix Kγ for the arc used. This can be done by calculating the average of factors 
Kγ, α within the used arc between gantry angle steps of 10°. [28] 
               
  
Image 7: The relation between the gantry angle and the direction of the radiation to the measuring point 
of the middle chamber of the matrix in the created system. 
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Dose calculations using treatment planning systems 
 
The created verification system is investigated also by calculations done by treatment 
planning systems. With these investigations it is possible to analyze the features of the 
created verification system, and to compare the results of the measurements with 
calculations. It is also possible to compare the accuracies and features of the calculation 
algorithms of the treatment planning systems. The calculations are done by the Monte 
Carlo algorithm of Monaco 2.0.3 and kernel-based analytical anisotropic algorithm of 
Eclipse 8.6. The calculations are done by similar fields as in the measurements using 
energy of 6 MV. The calculations are done by steps of gantry angles between 10°, but 
between gantry angles from 60° to 120° the used steps are 5°. The calculated dose by 
every field is estimated at the same point, where the measurement point of the middle 
chamber is. By using the same parameters as in the investigations of the dependence of 
the measuring angle and the effect of attenuation by the treatment table, it is possible to 
take these results under the same analyses. All these measured and calculated doses are 
inserted in a graph with the same scale, in which the measured dose with a gantry angle 
of 0° is set as 1,000. All the other measured and calculated doses are set against this 
value using equation 
 
  KR, α = MD0° / Dα                     (12) 
 
where KR, α is a relative factor compared to the measured dose with a gantry angle of 
0°, MD0° is measured dose with a gantry angle of 0° and Dα is the measured or 
calculated dose with a gantry angle of α. The measured doses with gantry angles, in 
which the effect of attenuation by the treatment table is relevant are also corrected by 
correlation factor KT, α , and inserted as a graph in the same graphics along with the 
others. 
 
 
4.2 The Ball Test 
 
It is pivotal to assure the reliability of cooperation of Monaco treatment planning 
system version 2.0.3 and Elekta Axesse linear accelerator in treatments of VMAT plans 
with all energies. This goal can be represented briefly by dividing it into three 
categories of the essential properties and phases of VMAT planning and treatment. 
These are quality assurance of the treatment planning system’s fluence distribution 
optimization module, quality assurance of the treatment planning system’s sequencer 
and quality assurance of the accelerator’s dynamic dose delivery process [23].  
 
To investigate these issues the ball test is created. The idea is to have a mutual concept 
in the investigated plans, that is, first of all challenging for the system to realize, and 
secondly, easy to manipulate by little changes in treatment planning without losing the 
main parts of the concept. The ball test is realized with the created plan verification 
system. The search of the answers is started with treatment planning by creating, 
calculating and investigating plans. A suitable spectrum of these plans is treated and 
measured. Estimations of implementation capability of the system are done by 
equivalences between the calculated fluence distributions and the measured dose 
distributions.  
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4.2.1 Treatment planning of the Ball Test 
 
The main goal for treatment planning in the ball test is quality assurance of treatment 
planning system’s fluence distribution optimization module. However, in treatment 
planning it is also a goal to create plans, which are suitable for dose distribution 
measurements. For these purposes a plan with a regular size target ball added in with an 
alterable constraint ball is constructed. The balls’ middle points are positioned towards 
the top of the matrix’s middle chamber. The construction is shown in image 8. For all 
the plans the radius of the target ball is set as six centimetres and the target dose at 2,0 
Gy. However, constraint ball’s maximum dose is placed first in priority for the 
treatment planning system. This dose limit is changeable for the plans so that the 
capability of the system to perform with high gradients can be investigated. Also the 
constraint ball’s radius differs between plans. All the other parameters in treatment 
planning are set suitable for clinical treatment planning and are kept constant in all the 
plans. Calculations are performed with two phase optimization. After the first phase 
calculation using the Pencil beam convolution algorithm, the second phase is calculated 
using the Monte Carlo algorithm. 
 
                        
                                                                                           
Image 8: Construction of the ball test. At left three dimensional view, and at right a transversal slice at 
isocenter, of a CT image, in which the target ball is drawn by orange and constraint ball with radius of 
three centimetres is drawn by pink. 
 
 
By forcing plans to the limits of the calculation algorithms, it is possible to find out; 
first of all, the limits of the treatment planning system, but also to analyze whether 
pushing the calculation system by challenging constraint-target dose differences, i.e. 
gradients, matter to actually treated dose distributions by decreasing the equivalence 
between the calculated and treated dose distributions. These are investigated by plans 
where the constraint ball’s radius is set as three centimetres. For the first plan, the 
constraint ball’s dose limit is set off. With this plan, called R3D100%, the calculation 
algorithms can concentrate on just producing uniform dose distribution for the volume 
of target ball. For the second plan the constraint ball’s dose limit is set to two thirds of 
the target dose. In this plan, called R3D66%, the calculation algorithms have to struggle 
with the limit of the constraint ball while producing enough dose to the target area. 
With the three centimetre radius constraint ball it is investigated how low the dose limit 
can be pushed, so that calculation algorithms are able to finish the calculation and at 
which point of dose limit the calculation system warns the user that a plan is infeasible. 
The plan with the lowest dose limit of the constraint ball, which calculation algorithms 
calculate without warnings, is named as R3Dmin%. It is also investigated how well the 
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calculation algorithms are performing by changing the size of constraint ball, and 
whether it matters to the accuracy of production of the dose distribution. These are all 
investigated with the constraint ball’s dose limit of two thirds of the target dose. 
Calculations are done with constraint balls’ radius’ of one and five centimetres. These 
plans are named as R1D66% and R5D66%, respectively. 
 
 
4.2.2 Dose distribution measurements with matrix 
 
By measuring the dose distributions of the created plans and comparing the results with 
the same plan’s calculated fluence distribution at the coronal slice on top of the 
chambers, quality assurance of the treatment planning system’s sequencer and 
accelerator’s dynamic dose delivery process with VMAT treatment plans can be done. 
The measured dose distributions by the created verification system will be correlated by 
the calculated calibration factor for a 360° VMAT treatment plan with used energies. 
Evaluations of dose distributions are done by a gamma index method. 95 % of the 
chambers in the area of radiation should pass typical accuracy limits of 3 mm and 3 % 
between the calculated and measured point doses to confirm equivalence between the 
calculated and delivered dose distributions [23][24]. In this test an area, where the 
planned dose is about at least 50 % of the target dose, is considerer separately. This 
area includes the 225 most centrally located chambers of the matrix. By comparing the 
percentages of the passed chambers between the plans, it is possible to analyze the 
possible effect of high gradients or different size of constraint on the realization 
accuracy of the plans. 
 
Also repetition accuracy of a treatment is tested by measuring dose distribution of the 
delivered plan R3D66% three times consecutively with the energies used. In the results 
the repetitive measuring accuracy of a chamber, which is measured during the 
investigations for the created verification system, is also taken into consideration. 
However, the measured dose distributions of the same plan delivered repetitively are 
compared by a gamma index method with accuracy limits of 0.5 % and 0.5 mm. The 
plan R3D66% with energy of 6 MV is measured also three times after re-positioning 
the created system in order to estimate any possible error in arrangements made by the 
user. 
 
 
4.2.3 Dose distribution measurements with radiochromic film 
 
In the dose distribution measurements done by the matrix, the size of the chambers and 
intervals between them set uncertainty into spatial resolution. A higher-resolution 
detector such as radiochromic film might be preferable for such measurements of dose 
distribution [2]. However, the clinical practicality of the matrix encourages the use of it 
as a dose distribution measurement device in the long-term. In order to ensure the 
required accuracy of the matrix, both spatially and by dosimetry, it is important at least 
to determine possible relative inaccuracies in spatial resolution, and also with dose, 
compared to radiochromic film dosimetry. 
 
For this investigation the film dosimetry equipment and methods used in HUCH are 
brought into play. The used film is Gafchromic EBT2 (International Specialty Products, 
NJ, USA), which is developed specifically for dosimetric working in a radiation 
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therapy environment, and can resolve features with spatial resolution to at least 0.1 mm 
[21]. The 0.25 mm thick film is handled and measured by the instructions from the 
manufacturer [21]. The output factor of the exact film used in the measurements is 
determined by the ratio of the detector response per monitor unit for a given field, to 
that, for the reference field at a reference depth [2]. The daily dose rate of the linear 
accelerator, which is used for calibration to be congruent with the analyzing methods 
used in HUCH, is checked by a monitor test device called LinaCheck (PTW Freiburg 
GmbH, Germany) [29]. In the measurements five different amounts of doses are used, 
which are decided to be in a broad enough range compared to the impending dose 
distribution in order to ensure accuracy of the calibration especially in the most 
significant range of doses. With a relative amount of monitor units for each dose, three 
measurements are done by field size of 5 · 5 cm to 3 · 3 cm pieces of the same sheet of 
film as the dose distribution measurement is done. The pieces of film in the calibration 
measurements are positioned in the middle of a 10 cm pile of solid water slabs with a 
source-to-detector distance of 100 cm. These fifteen pieces of film are scanned three 
times each with DosimetryPRO Advantage red densiometer (Vidar Systems 
Corporation, VA, USA) [30]. The densiometer is linear in the condition of the 
investigation with its 16-bit scale of colouring, which provides a spatial resolution of 
0.08 mm [30]. By taking an average of these doses the system can be calibrated to be 
able to analyze the actual measured dose distribution of the investigation. It is also 
scanned three times, and the average is used. 
 
The film measurement is done by the plan R3D66% with energy of 6 MV. The five 
doses for calibration measurements are 1.0, 1.3, 1.7, 2.0 and 2.4 Gray. In the actual 
dose distribution measurement a 19 · 15 cm piece of the sheet of film is positioned into 
the created verification system on top of the matrix. So, the measuring points of the 
chambers of the matrix are 0.5 cm under the film. At the level of the film the target ball 
is 11.96 cm and the constraint ball 5.92 cm in diameter. Compared to the measuring 
level of the chambers, changes in the positions of the outer and inner gradients are 0.02 
cm and 0.04 cm, respectively. However, the plan is measured by the matrix at the same 
time, and the measured dose distribution by the film is compared to the measured dose 
distribution by the matrix. The attention is paid most of all to the sharpness of the 
gradients. This investigation also offers an indication of the reliability and accuracy of 
the created verification system.  
 
 
4.3 Verification of clinical test VMAT treatment plans 
 
Before starting to plan VMAT treatments for patients, also five clinical test plans are 
created by planning CT images of previously treated patients. Verification of these 
clinical test VMAT treatment plans are performed by measuring dose distributions with 
the created system by quality assurance mode without rotating gantry and using the 
original plan. Quality assurance mode with a static gantry angle of 0° is measured four 
times with different isocenters to increase resolution relating to the gaps between the 
ionization chambers of the matrix. First measurement is done by positioning the 
isocenter in the middle of the matrix and the next one 5 mm aside from the middle point 
by moving the treatment table. Then the last two measurements are done likewise by 
changing the place of the isocenter, so that measurements are done with isocenter in 
every corner of a square. These dose distributions are merged by the software of the 
matrix. The second phase of these plan verification measurements is done by measuring 
 21
the actual treatment plan by it’s actual planned rotating gantry with the created VMAT 
plan verification system. The calibration factors for the measured dose distributions in 
each case are entered to the system. The measured dose distribution maps are compared 
with the calculated ones. 95 % of the chambers inside about an area of 50 % isodose 
should pass accuracy limits of 3 mm and 3 % between the calculated and measured 
point doses [23][24]. Also the percentages of passed point doses with the same 
accuracy limits inside about an area of 10 % isodose are calculated. 
 
If the results of the ball test and the clinical tests are acceptable, VMAT treatment 
planning for clinical cases can be launched. Additionally, all of the VMAT treatment 
plans of every patient are delivered in their actual forms and measured with the created 
system. Also one of the treatment plans of each patient is measured by quality 
assurance mode without rotation of the gantry. The results are analyzed, before starting 
the treatment with the plans. 
  
 
4.4 Patient positioning using the CBCT system and the robotic 
treatment table Hexapod 
 
From a clinical point of view, there are two main goals in CBCT imaging of patients 
with bladder cancer. First, to use such an imaging preset which enables sufficient image 
quality to determine daily position of the bladder with as little dose as possible. Second, 
to be able to make adjustments on patient positioning by position of the bladder instead 
of just extrinsic markers clinically accurate enough to realize treatments as planned. In 
order to reach these goals a possibility to create new CBCT imaging presets with 
different properties is investigated. Also tests for imaging, automatic matching and 
patient positioning accuracies need to be performed before determining strategies for 
CBCT imaging and position correction of the patients. It would be desirable to use the 
grey-value algorithm in automatic matching, because by the use of it, the matching 
could be done automatically by the positions of the internal organs. In addition the 
encouraging results of investigations about the accuracy of the grey-value algorithm to 
be precise, and even more accurate than the bone algorithm in automatic matching, 
motivates the investigations using it [11]. By introducing practical strategies for the 
whole process of CBCT imaging and patient repositioning also the total treatment time 
could be reduced. 
 
 
4.4.1 Different presets for the CBCT imaging 
 
The most suitable presets, i.e. imaging settings including for example tube current and 
voltage, installed in Xvi for CBCT imaging in bladder cases are presets called Prostate 
M10 and Prostate M10 Fast using counter clock-wise direction of gantry rotation. From 
the information offered by the manufacturer the Prostate M10 Fast produces less 
absorbed dose into a patient and is twice as rapid compared to Prostate M10 preset [10]. 
Still image quality remains high, which encourages investigating the possibility of 
decreasing the dose and speeding up the imaging at the expense of the image quality of 
the preset. However, image quality comes as number one in priority in the 
investigations, because it has to be clinically good enough to visualize clearly most of 
all the walls of the bladder.  
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The creation project of the presets is realized by modifying the parameters of the 
Prostate M10 Fast preset. The parameters can be adjusted only in limited scales, set by 
the manufacturer, which have to be considered while changing the parameters of the 
presets [10]. However, it is possible to modify many of them as long as the limited 
scales of the parameter combinations are respected. The parameters that are most 
reasonable to concentrate on modifying, in order to achieve the goals, are tube voltage, 
current, time, degrees of rotation, speed of the gantry and number of frames. By 
varying the parameters several presets are constructed. Into all the presets the imaging 
direction is set in the counter clock-wise direction. However, the presets, which are 
introduced clinically, have to pass first of all tests of image quality and automatic 
matching, and in addition the measurements of produced absorbed dose. 
 
 
Image quality and accuracy of automatic matching between the presets 
 
By the created presets the CBCT imaging needs to be performed by imaging as human-
like structure as possible in order to visualize the results of the presets. A phantom is 
created using the real organs of a pig and a cow bought from a butcher. Kidneys, liver, 
heart, tongue, pieces of fat and thigh bone of a pig are inserted into a plastic bag with 
the cartilage of a cow. Also a small plastic bag filled with air and one filled with urine 
are plot in between the organs. A piece of aluminium, which is the same size as gold 
seeds used in the prostate for tracking, is inserted into the heart. The plastic bag with 
the substances is covered with cow’s blood and sealed. The bag is inserted into a water 
proof cool box made out of expanded polystyrene. It is filled by water and put into a 
freezer, so that the entireness would stay stable in the box as an ice cube. During the 
measurements the cool box is sealed with a cover, so that melting of the ice is 
sufficiently slowed down at least for couple of hours. The created internal organ 
phantom is imaged by CT to have a reference image for the investigations, which is 
shown in image 9. An isocenter is set to the piece of aluminium, and markings are 
drawn on the box by the positioning lasers.  
 
  
 
 Image 9: Transversal view of a CT image of the created internal organ phantom. 
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In the investigations the internal organ phantom is positioned on the treatment table, as 
shown in image 10, and CBCT imaging is performed by the created presets. With the 
ones, which create images with a level of image quality high enough for clinical 
applications, are then brought to the next step of the process. Using these presets, as 
well as with presets Prostate M10 and Prostate M10 Fast, imaging is performed to 
realize a comparable accuracy test of automatic matching between images performed 
by the presets. The test is done three times by positioning the internal organ phantom 
on the treatment table, so that the isocenter is moved a little at least in three dimensions. 
The variations are between 3 - 10 mm in translational directions and 0.3 - 1.0° in 
rotational directions. CBCT imaging is performed with each preset, and the image is 
compared to the reference CT image by automatic matching done by the grey-value 
algorithm of the software, which is adjusted to match the images by an area, which 
includes all the substances of the phantom. The suggested position corrections are 
written down, and compared to the ones suggested by the other presets in order to 
determine if the modification of the presets matter to accuracy of matching. In order to 
approve the created presets for clinical use by the automatic matching capabilities the 
results of automatic matching should recommend the same, or at least not alternations, 
over the limitations of the scales, positional corrections for all the presets. 
 
 
 
Image 10: The internal organ phantom positioned on the treatment table for CBCT investigations. 
 
 
Irradiated dose using the CBCT imaging with different presets 
 
The irradiated doses of the CBCT images performed with the presets, which are 
accepted into clinical use for bladder cases by image quality and matching accuracy 
tests, are measured with the CT thorax phantom, which is shown in image 11. The 
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phantom is cylinder shape with a radius of 16 centimetres, and it is positioned on the 
treatment table, so that the isocenter is set in the middle of the phantom. The material of 
the phantom is PMMA, in which there are openings for ionization chambers in the 
middle and also at depths of one and five centimetres from the surface. The used 
ionization chamber is the same as in the absolute dose measurements. It is positioned in 
the openings so that the longitudinal laser spots to the middle of the chamber. With 
each preset the doses are measured in the middle and at highest dose position at a depth 
of one centimetre from the surface. The position on the surface is determined by 
measuring with one of the created presets dose at three points on the surface; just on top 
of the treatment table, the opposite side from the table and at lateral side. With the one 
preset measurements are also done three times when the chamber is positioned in the 
middle, so that the measuring accuracy of the chamber and the repetitive irradiated dose 
by the imaging can be considered in analyses of the results. 
 
 
 
Image 11: CT thorax phantom used in measurements of CBCT dose. 
 
 
4.4.2 Automatic matching accuracy with grey-value algorithm 
 
Investigations on the accuracy of automatic matching are done by the internal organ 
phantom by positioning the phantom slightly apart from the isocenter of the treatment 
unit, and then imaging it using the CBCT preset Prostate M10 Fast in counter clock-
wise direction. The CBCT image is compared by automatic matching with the grey-
value algorithm of Xvi to the reference CT image. The grey-value algorithm is used in 
investigations because it concentrates on small changes in electron densities in the 
image, which make it the most feasible for matching by position of the organs. The 
recommended position corrections are compared to the actual position, where the 
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phantom was positioned. The positional errors are adjusted one by one to evaluate one 
direction at a time using a CBCT image. The directions are decided by taking into 
consideration the rotational direction of the imaging device, so that the directions 
against the frames and also along the frames are investigated. So, the individually 
investigated translational directions are longitudinal and lateral. Also, the rotational 
accuracies around lateral and vertical directions are investigated. For all of the 
directions the investigations are done by two divergences to also evaluate whether the 
amount of error matters to the matching accuracy. In the translational directions the set 
divergences of the phantom from the isocenter are 0.5 cm and 2.0 cm. In the rotational 
directions the transfers are 0.5° and 2.0°. So, all of the divergences are inside the 
moving range of the Hexapod treatment table Also investigations are made by adjusting 
the phantom using both 0.5 cm translational transfers and both 0.5° rotational transfers 
once. The same is done also by 2.0 cm and 2.0° transfers. In order to evaluate the 
possible range of errors made by the user in positioning of the phantom using lasers, 
adjustments and imaging are done three times using the 2.0 cm transfer in the lateral 
direction and using the 2.0° transfer around the vertical direction. After automatic 
matching, the results of it are also analyzed manually for every case. 
 
 
4.4.3 Movement accuracy of the CBCT equipment 
 
The repositioning accuracy of the CBCT system is also important to determine [12]. 
Clinically it is essential that the cooperation between CBCT imaging, matching by the 
software and the realized movements of the Hexapod treatment table work precisely 
together. The cooperation is investigated by double-checking the position of the 
internal organ phantom after realizing the recommended position corrections of 
automatic matching. Therefore, the phantom is positioned on the treatment table 
slightly apart from the actual isocenter at least in three dimensions. The movements are 
not more than 1.0 cm in translational directions nor over 1.0° in rotational directions. 
The CBCT imaging is performed by Prostate M10 fast. The image is matched by 
automatic matching of Xvi with the grey-value algorithm. The recommended position 
corrections are inserted into the iGuide software, by which the movements of the 
Hexapod treatment table are realized. After the movements of the treatment table, 
CBCT imaging is performed again, and automatic matching is implemented. It is 
observed if the position corrections recommended are null or at least inside the step 
ranges of the system. The process is carried out five times with different phantom 
positions in each case. 
 
 
4.5 Planning of the treatment process for the radiation therapy of 
patients with bladder cancer 
 
Because of the substantial improvements of the on-line adaptive method in the radiation 
therapy treatments of bladder cancer patients, the treatment planning process is built 
around the demands of the method. To answer the demands, the features of the linear 
accelerator Elekta Axesse and the treatment planning system Monaco are challenged. 
With VMAT planning it is a goal to find a suitable template, by which the target dose 
can be reached with minimum healthy tissue irradiation within as short treatment time 
as possible. There are also significant demands on accurate CBCT imaging with a 
minor dose and accurate patient positioning by six degrees of freedom. The final goal is 
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to be able to create instructions for the whole treatment process of patients with bladder 
cancer. 
 
The radiation therapy planning process for patients with bladder cancer is started by 
considerations of accurate patient positioning. There have been encouraging results of 
investigations to improve visualization of the bladder tumour in CBCT images using 
fiducial markers [31]. Therefore, an urologist injects drops of a x-ray contrast agent 
called lipiodol through a flexible cystoscope into the bladder wall days before planning 
CT imaging. About an hour before the CT imaging is started, patients are instructed to 
drink a lot of water and to urinate minutes before positioning on the CT imaging table. 
The first image is performed immediately, and the other three in intervals of fifteen 
minutes. With the help of the images, the isocenter is set and marked by tattooing 
points on patients’ skin at the crossroads shown by the positioning lasers. With each CT 
image an oncologist contours relative planning target volumes (PTVs) by the position 
of the tumour volume. [7] 
 
In actual treatment planning process, VMAT treatment plans are realized for every PTV 
individually. The goal is to implement a template in the treatment planning system for 
bladder cases. The template should include a suitable work-flow for the planning 
process and practical parameters for optimization. The investigations are realized by 
thorough treatment planning for patients with bladder cancer. As minimum criteria for 
the planning process, the objectives set by ICRU report 50 are used [32]. Using these 
objectives the minimum dose in the PTV should be at least 95 % and the maximum 
dose smaller than 107 % of the planned dose. After these criteria are filled, the 
concentration is on decreasing the dose in organs at risk and shortening the treatment 
time. It is important to explore the trade-off between plan quality and the efficiency of 
its delivery carefully for each individual case [4]. Especially with very complex cases 
in VMAT treatment planning, there might have to be compromises made between the 
quality of dose distribution and treatment time [4]. In order to realize these goals, 
concentration is focused on properties and parameters in the windows of treatment 
planning system called beam setup, segment shape properties, IMRT calculation 
properties and prescription. 
 
Before starting the treatment, the VMAT treatment plans are verified by dose 
distribution measurements. The verification method used in actual treatment plans is 
decided by the results of the ball test and verifications done by the clinical test VMAT 
plans. If the results indicate that the created verification system is reliable, it is 
introduced as a tool for the clinical treatment plan verification process. However, at 
least one plan of each patient is also measured using the previous method with quality 
assurance mode without gantry rotation. By analyzing the results, it is a goal to 
introduce a systematic long-term work-flow for the VMAT treatment plan verification 
process. 
  
In the treatment process, the patient is positioned carefully on the treatment table by the 
radiographers using the tattooed markings on the patient’s skin and lasers on the walls 
of the treatment room. The frame of the infrared reflectors is attached to the Hexapod 
treatment table on a place, where it is not between the radiation source and target 
volume, and the motorized table is set in its zero position so that the maximum range of 
corrections could be applied in all directions. The CBCT imaging is then performed to 
determine the on-line position and volume of the bladder. The used imaging preset is 
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decided by the results of the CBCT investigations. However, the CBCT imaging is 
performed always in the counter clock-wise direction in order to get the gantry close to 
the starting angles of the treatments in the end of imaging. Furthermore, the used 
matching and positioning correction strategy are resolved by the results of CBCT 
investigations. If the automatic matching with the grey-value algorithm is clinically 
accurate, the possibility of using automatic matching can be utilized. Because of the 
shifting places and volumes of organs in the pelvic area, the smallest PTV plus five 
millimetres is used as an automatic matching volume, and results of the automatic 
matching are reviewed manually. Any possible corrections to the patient position are 
made by the motorized table with six degrees of freedom, if the position correction 
investigation results are encouraging. If the dose of the CBCT images is noted to be 
relatively negligible with some presets, imaging is performed also immediately after the 
treatment. In these images the image quality is not crucial because imaging is not 
performed for accurate patient positioning. These images would provide information 
about the changes in bladder volume and movements of the organs that have occurred 
during the treatment. It is a goal to introduce function strategies also for these CBCT 
relating questions in the instructions for radiation therapy treatment of patients with 
bladder cancer. 
 
 
5 Results 
 
5.1 Results of the investigations on the created verification system 
 
5.1.1 Defined calibration factor for measured dose distributions 
 
Always before starting investigative measurements the daily conditions were 
determined. Air pressure and temperature were measured and entered into the matrix’s 
software. The relative measurements of dose rate were made with the energies used that 
day. Except on one measurement day, the calculated difference between daily dose rate 
and the reference dose rate using equation 6 was less than the measurement accuracy of 
the matrix. So, no corrections were made by this reason except on that one day. After 
daily conditions had been checked, the measurements and calculations were carried out 
as explained in section 4.1.1. These investigations were able to determine the 
calibration factors for the measured dose distributions. For 360° VMAT treatment plans 
with 6 MV energy calibration factor KC, 6x is 1.036 and with 10 MV energy KC, 10x is 
1.045. The factors behind these numbers are represented in the section by details. 
 
 
Results of calibration of the chambers of the matrix in order to be comparable 
with the chamber of absolute dosimetry and repetitive measuring accuracy of the 
chambers of the matrix 
 
Measurements were made first with the water phantom. The air pressure and 
temperature of the water inside the water phantom were measured and inserted into 
equation 2 to calculate the correction factor for the absolute chamber’s calibration 
factor’s pressure and temperature dependence. The percentage depth doses were 
measured with energies of 6 and 10 MV. These are shown in image 12. The absorbed 
doses in water were calculated for both energies using equation 4, where the doses at 
maximum points for energies of 6 and 10 MV were 0.999 Gy and 1.000 Gy, 
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respectively. Furthermore, the doses at a depth of 10 cm in water were 0.681 Gy and 
0.730 Gy, respectively. Using the equivalent measurements with the matrix, the 
calculated doses with 6 and 10 MV were 0.693 Gy and 0.734 Gy, respectively. A 
calibration factor to make the matrix comparable with the absolute dosimetry was 
calculated using equation 5, from which Km, 6MV was determined as 0.983 and Km, 10MV 
as 0.995. 
 
 
 
Image 12: Measured percentage depth doses. Blue graph represents the PDD of 6 MV and pink graph the 
PDD of 10 MV. 
 
The ranges of the measured doses of ten repetitive measurements made by the matrix 
with energies of 6 and 10 MV were from 0.884 to 0.888 Gy and from 0.935 to 0.938 
Gy, respectively. Moreover, the calculated averages were 0.8857 and 0.9368 Gy, 
respectively. By dividing the farthermost measured dose by the average it was 
calculated that the precision of the repetitive measurements are 0.2 % with both 
energies. 
 
 
Results of investigations on factor for eliminating the effect of attenuation by the 
treatment table 
 
Using the measured doses the factors KT, α were calculated using equation 8. These 
results are shown in image 13 as a graph. The average effect of attenuation by the 
treatment table was calculated for both energies. Then the factor for eliminating the 
effect of attenuation by the treatment table from dose distribution measurements with 
the created verification system for 360° VMAT treatment plans were calculated using 
equation 9 with both energies. The calculations reveal that KT,360°,6MV is 1.012 and 
KT,360°,10MV is 1.009. 
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Image 13: Factors to eliminate the effect of attenuation by the treatment table from different gantry 
angles. 
 
 
Angle dependence of the chambers of the matrix  
 
The correction factors for dependence of the measuring angle were calculated using 
equation 11 after finishing the measurements. A graph reconstructed by the calculated 
factors is shown in image 14. Using all these factors an average was calculated to get 
the factor Kγ for correcting the dependence of the measuring angle of chambers for the 
360° VMAT treatment plan verification with the created system. As a result of the 
calculations, the value of Kγ, 360° was specified as 1,041. 
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Image 14: Factors to correct the measuring angle dependence of the chambers of the matrix. 
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Results of measurements and calculations done with the created verification 
system 
 
These measurements and calculations were realized also as described in section 4.1.1. 
All the investigated point doses were compared to the measured dose with a gantry 
angle of 0° using equation 12. Based on these factors, four graphs were reconstructed 
and one further graph by eliminating the effect of the attenuation by the treatment table 
from the measured doses. These graphs are shown in image 15. 
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Image 15: Measurements and calculations made for the created verification system for VMAT treatment 
plans with energy of 6 MV. The measured doses are compared to calculations performed using analytical 
anisotropic algorithm of Eclipse and Monte Carlo of Monaco. Also the graphs of the measured doses 
correlated by table attenuation factor and measured doses from the gantry angle of 0° with relative 
measurement depths are shown. KR represents a relativity factor compared to the measured dose from a 
gantry angle of 0°, which is set as 1.000. 
 
 
5.2 Results of the Ball Test 
 
5.2.1 Comparisons between calculated plans 
 
In the planning process emphasis was placed on estimating the capability of the 
planning system to optimize fluence distribution with changing target sizes and limited 
constraint doses. It was also a goal to find the limits of the treatment planning system, 
where it will give an infeasibility warning to reach the set goals or not even reconstruct 
the fluence distribution map. This was tested using the constraint ball of radius 3 cm 
inside the target ball of radius of 6 cm. With both used energies the treatment planning 
system was able to optimize fluence distribution without problems till the situation, 
where the constraint ball’s dose limit were set at 60 % of the target dose. The dosage 
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statistics reached in targets and constraints are shown in table 1, for energy of 6 MV, 
and in table 2, for energy of 10 MV, in all investigated situations. The planning system 
was able to calculate also treatment plans even with the smaller constraint ball’s doses 
till 40 %, but it informed the user with a warning sign “infeasible” in the column of the 
constraint ball in the optimizing window. These plans were not even able to be treated 
at the linear accelerator. The accelerator’s software gave inhibit error of mlc. The 
treatment planning system was not even able to optimize plans with the smaller 
constraint ball’s dose than 40 % of the target ball’s dose. 
 
    Table 1: Statistics of calculations with energy of 6 MV. 100 % target dose is 50 Gy. 
 
6 MV Constraint Target 
Constraint’s 
radius / cm 
Constraint’s 
dose limit 
Volume 
where dose 
limit is 
crossed / % 
Hot Spot / 
Gy (% of 
dose limit)
Volume 
where target 
dose is 
reached /   
% 
Hot Spot / 
Gy (% of 
dose limit)
3 cm 100 % - - 97.0 54.5 (109) 
3 cm 66 % 54.5 37.4 (113) 6.6 50.8 (102) 
3 cm 60 % 38.8 33.2 (111) 0.0 44.8 (90) 
5 cm 66 % 69.6 35.9 (109) 0.0 46.0 (92) 
1 cm 66 % 60.0 36.3 (110) 69.0 55.2 (110) 
 
 
    Table 2: Statistics of calculations with energy of 10 MV. 100 % target dose is 50 Gy. 
 
10 MV Constraint Target 
Constraint’s 
radius / cm 
Constraint’s 
dose limit 
Volume 
where dose 
limit is 
crossed / % 
Hot Spot / 
Gy (% of 
dose limit) 
Volume 
where 
target dose 
is reached / 
% 
Hot Spot / 
Gy (% of 
dose limit)
3 cm 100 % - - 99.0 55.8 (112) 
3 cm 66 % 61.1 37.0 (112) 8.9 51.5 (103) 
3 cm 60 % 43.0 33.5 (112) 0.3  50.0 (100) 
5 cm 66 % 68.4 36.0 (109) 0.0 45.5 (91) 
1 cm 66 % 60.1 36.7 (111) 63.7 54.0 (108) 
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5.2.2 Comparisons between measured and calculated dose distributions 
 
Results of measurements made using the matrix 
 
All the treatment plans of the ball test were measured and calibrated according to the 
way introduced in section 4.2.2. The percentage proportions of the point doses 
measured by the chambers, which passed the accuracy limits in the area of 15 · 15 most 
middle chambers, and in the whole irradiated area of 27 · 15 chambers, are introduced 
in table 3 for every measured plan. Nine plans out of ten passed the accuracy limits of 3 
% and 3 mm with at least 95 % of accepted point doses in the 225 closest chambers to 
the isocenter. By examining the results of plan R3D66% with energy of 6 MV it can be 
observed, that 99.1 % of the 225 most centrally located chambers to the isocenter, and 
99.0 % of the 405 chambers, which were in the irradiated area, passed the accuracy 
limits. This can be observed also from image 16 showing a coronal slice of the 
measured dose distribution of plan R3D66% at the level of the measuring points of the 
chambers. In the image, the red squares indicate that the measured dose by the chamber 
did not pass the set accuracy limits. The profiles of the plan at the isocenter are shown 
in images 17 and 18. 
 
Table 3: Percentage of accepted point doses measured by the chambers inside about an area of 50 % 
isodose. In parentheses the percentage of accepted point doses in the whole irradiated area. 
 
6 MV 10 MV Constraint’s 
radius/ cm 
and dose/ % 100 % 66 % Min. 100 % 66 % Min. 
5 cm  96.4 % (97.3 %)   
96.4 % 
(90.6 %)  
3 cm 100.0 %  (99.5 %) 
99. 1 %  
(99.0 %) 
98.7 %  
(98.5 %)
100.0 % 
(99.1 %) 
99.6 % 
(91.4 %) 
94.7 % 
(88.9 %)
1 cm  98.7 % (97.5 %)   
99.6 % 
(96.8 %)  
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Image 16: Coronal slice of measured dose distribution of plan R3D66%6MV at the level of the 
measuring points of the chambers. Profiles: orange = 100 %, yellow = 80 %, green = 50 %, blue = 20 % 
and dark blue = 10 % of the target dose. Red squares indicate that the measured dose by the chamber did 
not pass the set accuracy limits. 
         
 
Image 17: Profiles of left to right directions at the isocenter of the calculated and measured dose 
distributions of plan R3D60%6MV. The red line signifies the calculated dose profile and squares 
measured point doses of the chambers. The green squares indicate the passed point doses and the red 
squares the failed ones. 
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Image 18: Profiles of gantry to table directions at the isocenter of the calculated and measured dose 
distributions of plan R3D60%6MV. The red line signifies the calculated dose profile and squares the 
measured point doses of the chambers. The green squares indicate the passed point doses and the red 
squares the failed ones. 
 
By turning attention to the middle columns of table 3, it can be seen with both energies, 
that by removing the dose limit of the 3 cm radius constraint ball, all the point doses of 
the 225 most centrally located chambers are passed. By examining the column in the 
other direction, where the dose limit of the constraint ball was tightened as low as the 
treatment planning system permitted without warnings, the percentage of passed point 
doses descended. By changing the radius of the constraint ball from 3 cm to 5 cm with 
a dose limit of 66 % of the target dose, the number of passed point doses also 
decreased. By reducing the radius of the constraint ball with the same dose limit to 1 
cm, the number of passed point doses also decreased with energy of 6 MV; however 
with 10 MV, the number of passed point doses remained the same with the 225 most 
centrally located chambers, and increased by considering all the chambers in the area of 
irradiation. 
 
In order to investigate the reliability of the congruency of the measured dose 
distributions in repetitive treatments, plan R3D66% was measured three times with 
both energies, and also another three times by repositioning with energy of 6 MV. By 
comparing all cases of measured dose distributions from the same session, using the 
accuracy limits of 0.5 mm and 0.5 %, 100 % of the 225 most centrally located 
chambers’ point doses passed. Also more than 95 % of all the 405 point doses 
measured by the chambers in the irradiated area passed the accuracy limits. By 
comparing the measured dose distributions of 6 MV before and after re-positioning, 
more than 95 % of the point doses measured by the 225 most centrally located 
chambers passed the accuracy limit of 0.5 % only by relaxing the distance accuracy 
limit to 1.5 mm. 
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Results of measurements made using radiochromic film and the matrix together 
 
The used sheet of a radiochromic film was irradiated, measured and calibrated as 
explained in section 4.2.3. Plan R3D66% was measured by the film and the matrix 
together. The isodoses of the dose distributions measured by the film and the matrix are 
shown in image 19. From the image, the resolution limitations of the measuring devices 
can be observed. In the isodose measured by the matrix the measuring points can be 
observed by squares as a uniform dose, because the point doses of the chambers are not 
averaged with the ones around them. Both detector systems’ profiles at the isocenter in 
the directions of left to right and gantry to table are shown in images 20 and 21, 
respectively. In these images the measured dose by the matrix is represented by green 
graphs in which the measured point doses using chambers are shown by steps in the 
graphs. The red graphs represent the measured doses by film. The borders of the film 
can be observed by the end of the graphs earlier, than the graphs of profiles measured 
by the matrix.  
 
       
 
Image 19: Isodoses of the measured dose distributions. On the left the measured dose distribution by 
radiochromic film on top of the matrix and on the right the measured dose distribution by the matrix, 
where the measured dose by each chamber is shown as squares with uniform dose in the area. 
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Image 20: Profiles of left to right directions of measured dose distributions of plan R3D60%6MV. The 
red line signifies the measured dose profile using the film and the green line the measured point doses by 
the chambers. 
 
 
 
Image 21: Profiles of gantry to table directions of measured dose distributions of plan R3D60%6MV. 
The red line signifies the measured dose profile using the film and the green line the measured point 
doses by the chambers 
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5.3 Results of comparisons between calculated and measured dose 
distributions of clinical test VMAT treatment plans 
 
Five clinical test plans were measured with the created verification system using both 6 
and 10 MV energies. The dose distributions of all the test plans were measured as 
planned with 360° gantry rotation and by quality assurance mode without gantry 
rotation. The dose distributions were analyzed as discussed in section 4.3. For the 
measured dose distributions, the determined calibration factors were used. It was 
calculated that the percentage of the chambers, which had measured acceptable point 
doses inside the set accuracy limits in an area of about 50 % isodose were between 95.3 
% and 100.0 % with the 6 MV energy plans, and between 95.1 % and 100.0 % with the 
10 MV energy plans. The percentage of passed point doses in an area of about 10 % 
isodose was between 93.8 % and 96.8 % with the 6 MV energy plans, and between 93.4 
% and 95.5 % with the 10 MV energy plans. The results of the verifications measured 
by quality assurance mode without gantry rotation correlated very well with the 
corresponding 360° plan verifications. 
 
 
5.4 Results of investigations on patient positioning 
 
5.4.1 Created presets for the CBCT imaging 
 
There were three presets created, which were sufficient for clinical imaging of patients 
with bladder cancer. These presets were named as Bladder A, B and C. It was noticed 
during testing that the parameters which affect the imaging time cannot be decreased 
from the values in preset Prostate M10 Fast in order to avoid significant artefacts in the 
images. Therefore, the imaging time with all the sufficient created presets was 60 
seconds, and the focus was on decreasing the amounts of volts and amperes per second 
in order to minimize irradiated doses. 
 
 
Results of automatic matching accuracy between the presets 
 
Investigations to compare the equivalence of automatic matching between the created 
and the original presets were realized as explained in section 4.4.1. The preset Prostate 
M10 was chosen as the reference preset. The recommended position corrections in six 
dimensions by the other investigated presets were compared to the ones recommended 
by the reference preset. Using the three measurements with different positions of the 
internal organ phantom, there was not suggested more than 0.01 cm or 0.1° different 
corrections from the ones recommended by the reference preset. Nor were larger 
differences than those between the recommendations by any other presets. The results 
of the measurements are shown in table 4. 
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Table 4: Comparisons of matching accuracies between the presets. Prostate M10 is the reference preset.  
 
Preset Measurement 1 Measurement 2 Measurement 3 
Prostate 
M10 
Reference 
   tx = 0.73 cm      rx = 0.8° 
   ty = 0.41 cm      ry = 359.9°
   tz = 0.32 cm      rz = 359.9°
 tx = 0.25 cm     rx = 0.4° 
 ty = 0.07 cm     ry = 359.1°
 tz = -0.06 cm    rz = 358.6°
tx = 0.38 cm        rx = 0.4° 
ty = -0.01 cm      ry = 1.0° 
tz = 0.32 cm     rz = 358.2°
Prostate 
M10 Fast 
∆tx = 0.00 cm    ∆rx = +0.1° 
∆ty = +0.01 cm  ∆ry = +0.1° 
∆tz = 0.00 cm     ∆rz = -0.1° 
∆tx = 0.00 cm   ∆rx = -0.1°
∆ty = -0.01 cm ∆ry = +0.1°
∆tz = 0.00 cm   ∆rz = 0.0° 
∆tx = 0.00 cm   ∆rx = -0.1°
∆ty = -0.01 cm   ∆ry = 0.0°
∆tz = 0.00 cm   ∆rz = +0.1°
Bladder A 
∆tx = -0.01 cm   ∆rx = +0.1° 
∆ty = +0.01 cm  ∆ry = +0.1° 
∆tz = 0.00 cm     ∆rz = 0.0° 
∆tx = 0.00 cm   ∆rx = 0.0° 
∆ty = 0.00 cm  ∆ry = +0.1°
∆tz = 0.00 cm    ∆rz = 0.0°
∆tx = -0.01 cm   ∆rx = 0.0°
∆ty = 0.00 cm  ∆ry = +0.1°
∆tz = 0.00 cm   ∆rz = +0.1°
Bladder B 
∆tx = 0.00 cm     ∆rx = 0.0° 
∆ty = +0.01 cm  ∆ry = +0.1°
∆tz = -0.01 cm    ∆rz = -0.1°
∆tx = 0.00 cm    ∆rx = 0.0°
∆ty = 0.00 cm  ∆ry = +0.1°
∆tz = 0.00 cm    ∆rz = 0.0°
∆tx = -0.01 cm   ∆rx = 0.0°
∆ty = 0.00 cm  ∆ry = +0.1°
∆tz = 0.00 cm   ∆rz = +0.1°
Bladder C 
∆tx = 0.00 cm    ∆rx = +0.1° 
∆ty = +0.01 cm  ∆ry = +0.1°
∆tz = 0.00 cm     ∆rz = -0.1° 
∆tx = 0.00 cm   ∆rx = -0.1°
∆ty = -0.01 cm ∆ry = +0.1°
∆tz = 0.00 cm    ∆rz = 0.0°
∆tx = 0.00 cm    ∆rx = 0.0°
∆ty = 0.00 cm  ∆ry = +0.1°
∆tz = -0.01 cm    ∆rz = 0.0°
 
 
Measured irradiated doses of the presets 
 
The irradiated doses of the presets sufficient for imaging patients with bladder cancer 
using the information about image quality was measured as described in section 4.4.1. 
Using the preset called Bladder A, the measurements were made three times by the 
chamber positioned in the middle of the CT thorax phantom. The measured doses were 
7.5, 7.5 and 7.2 mGy. With the preset Bladder A also the doses on the surface at three 
different positions were measured. The dose close just above the treatment table was 
11,0 mGy, on the lateral side of the phantom 11.5 mGy and in the opposite direction 
from the table 11.7 mGy. So, the dose measurements on the surface of the phantom 
were made in the opposite side from the treatment table. The results of the 
measurements are shown in table 5. 
 
Table 5: Measured absorbed doses in the middle of the CT thorax phantom and at the maximum dose 
point on the surface of the phantom using the presets. 
 
Preset: Dose at Isocenter (mGy) Dose max. on surface (mGy) 
Prostate M10 20.5 35.7 
Prostate M10 Fast 11.2 18.5 
Bladder A 7.5 11.7 
Bladder B 4.0 6.7 
Bladder C 3.0 4.5 
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5.4.2 Results of automatic matching accuracy with grey-value algorithm 
 
The investigations were realized as planned in section 4.4.2. During the investigations, 
where concentration was focused only on one direction at a time, the largest margins 
between planned position correction and the recommended one was 0.08 cm in 
translational directions and 0.2° in rotational directions. The investigation using a 
displacement of 2.0 cm in the lateral direction was repeated three times. The sizes of 
the recommendations were 2.02 cm, 2.00 cm and 2.08 cm, and the average of these was 
calculated to be 2.03 cm. The investigation using a displacement of 2.0° around the 
vertical axis was repeated three times. The sizes of the recommendations were 2.0°, 
1.8° and 1.9° and the average of these was calculated as 1.9°. In the investigations, 
where the displacements were realized in four dimensions together with smaller 
investigated margins, the sizes of recommendations were almost as accurate as in the 
investigations of one direction in each case, but with larger margins the 
recommendations were unrealistic. All the results are shown in table 6. 
 
Table 6: Results of investigations into automatic matching accuracy with grey-value algorithm. 
 
Direction of the displacement Size of the displacement Size of the recommendation 
0.50 cm 0.45 cm 
Lateral (tx) 
2.00 cm 2.03 cm 
0.50 cm 0.54 cm 
Longitudinal (ty) 
2.00 cm 2.05 cm 
0.5° 0.7° 
Around lateral axis (rx) 
2.0° 2.1° 
0.5° 0.5° 
Around vertical axis (rz) 
2.0° 1.9° 
    tx = 0.50 cm        rx = 0.5° 
    ty = 0.50 cm        ry = 0.0° 
    tz = 0.00 cm         rz = 0.5° 
    tx = 0.42 cm        rx = 0.7° 
    ty = 0.38 cm        ry = 0.1° 
    tz = 0.07 cm         rz = 0.6° tx, ty, rx and rz     tx = 2.00 cm        rx = 2.0° 
    ty = 2.00 cm        ry = 0.0° 
    tz = 0.00 cm         rz = 2.0° 
     tx = 2.12 cm       rx = 2.6° 
     ty = 1.08 cm       ry = 346.9° 
tz = 0.92 cm        rz = 5.5° 
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5.4.3 Results of movement accuracy of Hexapod treatment table using the 
CBCT system 
 
The investigations were realized as described in section 4.4.3. The recommended 
position corrections of the software after the first CBCT imaging was recorded and 
realized by the movements of the Hexapod treatment table. Moreover, the 
recommended position corrections after the second CBCT imaging were recorded. Both 
recommendations are shown in table 7 in all five cases. The recommendations for 
patient positioning after the second CBCT imaging are in same magnitudes in four 
cases, where the recommendations in translational directions are from 0.00 cm to 0.02 
cm, and in rotational directions from 0.0° to 0.2°. In one case, the recommendations 
after the second CBCT imaging differed from the others by larger recommendations.  
 
Table 7: Recommended and realized position corrections after the first CBCT imaging and the 
recommended position corrections by another CBCT imaging after realizing the position corrections.  
 
Case Recommended and realized position corrections  
Recommended position 
corrections after 2nd imaging 
1 
        tx = 0.78 cm         rx = 0.9° 
        ty = 0.42 cm         ry = 0.0° 
        tz = 0.27 cm         rz = 359.9° 
         tx = -0.01 cm      rx = 0.0° 
         ty = 0.00 cm       ry = 0.0° 
         tz = 0.02 cm        rz = 0.0° 
2 
        tx = 0.36 cm        rx = 0.6° 
        ty = 0.33 cm        ry = 0.9° 
        tz = 0.01 cm         rz = 0.6° 
         tx = 0.03 cm        rx = 0.2° 
         ty = 0.01 cm        ry = 359.2° 
         tz = 0.07 cm         rz = 0.0° 
3 
        tx = 0.38 cm        rx = 0.7° 
        ty = 0.34 cm        ry = 0.1° 
        tz = 0.07 cm         rz = 0.6° 
         tx = 0.02 cm         rx = 0.0° 
         ty = 0.01 cm         ry = 0.0° 
         tz = 0.01 cm         rz = 359.9° 
4 
        tx = 0.47 cm        rx = 0.4° 
        ty = -0.02 cm       ry = 1.0° 
        tz = 0.58 cm         rz = 359.1° 
         tx = -0.01 cm        rx = 0.0° 
         ty = -0.01 cm        ry = 359.9° 
         tz = 0.00 cm         rz = 0.0° 
5 
        tx = -0.61 cm        rx = 0.2° 
        ty = -0.28 cm        ry = 0.1° 
        tz = 0.26 cm          rz = 359.4° 
         tx = 0.00 cm         rx = 0.0° 
         ty = -0.01 cm        ry = 359.8° 
         tz = 0.02 cm         rz = 0.1° 
 
 
5.5 Instructions for the radiation therapy process of patients with 
bladder cancer and first clinical experiences 
 
Between February and May 2011 at HUCH there were in total five patients treated 
radically for bladder cancer using radiation therapy. In two of the cases the whole 
bladder and in three of the cases only part of the bladder wall was treated. For all of the 
patients lipiodol was injected into the tumour area in bladder wall and CT imaging was 
performed as described in section 4.5. For two of the patients only three different 
targets, instead of the intended four, were designed, because of the relatively small 
changes in bladder volume between CT images. The planned target doses were between 
52.5 and 64 Gy. The first three patients were treated using photon energy of 6 MV. 
After receiving calculation data for the treatment planning system with photon energy 
of 10 MV from manufacturer, the other two patients were treated with this energy. The 
other properties and parameters of the treatment planning system were adjusted 
individually for each treatment plan of every patient. For all the patients suitable 
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treatment plans were planned according to the goals, and by considering the limitedness 
of realizing them all together comprehensively, as discussed in section 4.5. In all cases 
the absorbed doses in the PTVs were optimized between 95 % and 107 % of the 
planned dose. By struggling to minimize the dose in organs at risk in the vicinity of 
PTVs, there was small cold- and hot-spots aloud to the PTV in three cases. In partial 
bladder cases the edges of the PTVs, especially inside the bladder, were not considered 
as definite in order to minimize the dose in organs at risk.  However, in two of the cases 
the coverage of the whole PTVs were at least 95 % of the planned dose, and in three 
others the areas of cold-spots were not over 4 % of the PTV of the case. Image 22 
shows the isodoses in the treatment planning of a whole bladder case at isocenter level, 
and the dose-volume histogram of the case. In all of the cases the treatment times were 
between five and seven minutes. Using the experiences a workable template for the 
treatment planning process in bladder cases was determined. The template includes 
suitable work-flow for treatment planning with the properties and parameters used in it. 
The template is introduced in Appendix A as a part of the instructions for the radiation 
therapy treatment of patients with bladder cancer. 
 
    
                          
 
Image 22: Planned dose distribution in a case, in which the whole bladder was treated. The amounts of 
doses in contoured structures can be seen in DVH, where red indicates the PTV, yellow the hip bones, 
turquoise blue the bowels, brown the rectum and green the body. In the slices of planning CT images the 
107 % isodose is dark red, 95 % green, 80 % light blue, 50 % blue and 20 % dark blue.   
 
Using these results, introduced in section 5.3, of the 360° VMAT treatment plan 
verification measurements with the created system, a strategy for plan verification was 
created and used in all five cases. In the plan verification process all of the actual 
treatment plans are measured and analyzed by the created system. In addition, one plan 
of each patient is measured and analyzed also by the quality assurance mode without 
gantry rotation before starting treatment. If a plan measured only by the created system 
does not pass the set accuracy limits, it is measured and analyzed also by quality 
assurance mode without gantry rotation. One extra plan of two patients was measured 
also without gantry rotation to ensure the reliability of the specific plans. Using the 
measurements with the created system, the calculated percentage of ionization 
chambers, which had accepted measured doses inside the areas of about 50 % isodoses 
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were between 93.8 % and 99.7 % with the 6 MV energy plans and between 93.6 % and 
99.5 % with the 10 MV energy plans. The percentage of passed point doses inside the 
areas of about 10 % isodoses were between 93.8 % and 98.7 % with the 6 MV energy 
plans and between 92.6 % and 98.3 % with the 10 MV energy plans. Also by the 
information of these investigations, the dose distributions measured using the original 
plans and without gantry rotation are congruent. All of the plans were accepted for 
treatment. 
 
The positioning of the patients, the treatment table and the frame of the infrared 
reflectors were realized as suggested in section 4.5. Using the results of accuracy tests 
between different presets, also the created presets were included into clinical use. 
Relatively small doses irradiated by some of the presets enabled CBCT imaging also 
after the treatment in cases, where image quality was good enough with the created 
presets. A strategy for determination of an appropriate CBCT imaging preset for each 
patient individually was created by the results of CBCT investigations. Using the 
strategy patients are imaged with the preset Prostate M10 before, and with the preset 
Prostate M10 Fast after, the first fraction. If the image quality in the image performed 
after the fraction is sufficient, the preset will be used before the second fraction, when 
the image after the fraction is performed with the preset Bladder A. This is continued 
till the preset Bladder C or as long as image quality remains sufficient. Also the 
strategy is introduced in Appendix A by details. The strategy determined a suitable 
preset for CBCT imaging for each individual patient. In images 23 - 27 are shown 
CBCT images of a patient to whom the image quality of the preset Bladder C was 
sufficient. 
 
 
 
Image 23: Coronal view of a CBCT image using preset Prostate M10. Bladder of the patient can be seen 
in the middle of the image. Lipiodol is visible in the image as light area on the lateral wall of the bladder. 
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Image 24: Coronal view of a CBCT image using preset Prostate M10 Fast. 
 
 
 
Image 25: Coronal view of a CBCT image using created preset Bladder A. 
 
 
 
Image 26: Coronal view of a CBCT image using created preset Bladder B. 
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Image 27: Coronal view of a CBCT image using created preset Bladder C. 
 
The strategy for patient positioning with CBCT images was also planned using the 
results of the CBCT investigations. Automatic matching using the grey-value algorithm 
with the matching area suggested in section 4.5 was realized with all the patients. The 
results of automatic matching were reviewed manually always before deciding about 
the position corrections of a patient. Using the results of matching, the position 
corrections were done by the motorized Hexapod treatment table in six degrees of 
freedom with a range of corrections of 0.1 mm and 0.1°. After the corrections had been 
realized, the treatment was delivered. Also this part of the instructions for radiation 
therapy of patients with bladder cancer is introduced in Appendix A. 
 
 
6 Analyses of the Results 
 
6.1 Investigations on the created verification system 
 
6.1.1 Accuracy of the matrix as measuring device 
 
The investigations considered many issues relating to the measurement accuracy of the 
matrix as measuring device for VMAT treatment plan verification. The measured dose 
using the matrix was firstly, compared to the measured dose using the chamber of 
absolute dosimetry. Secondly, the repetitive measurement accuracy of the matrix was 
determined, and thirdly, the angle dependence of the chambers of the matrix was 
evaluated. Repetitive measuring accuracy was determined by ten measurements, which 
enable evaluation of the short term reproducibility of the matrix. It was noticeable 
during the investigations, that the first measurements by the matrix show relatively 
smaller doses. From this observation all the investigative measurements were started 
after the matrix had been switched on at least for ten minutes and the measured dose of 
daily dose rate measurements were stabilized. However, when the matrix was warmed 
up, the short term precision was only 0.2 % possible deviations of the mean, which is 
the same as in the investigations of Spezi et al also with PTW’s matrix [33].  However, 
these measurements were done only for the middle chamber of the matrix. Even though 
all the chambers are similar, there could be exceptional individuals. However, from the 
daily dose rate measurements with a 10.4 · 10.4 cm field and dose distribution 
measurements, there was no particular chamber noticed, which would have been 
repetitively showing a separate kind of dose according to the others.  
 45
Also the comparable measurement for the absolute dosimetry was made by the middle 
chamber of the matrix. In the investigations the amount of solid water set on top of the 
matrix was adjusted so that the depth to the measuring point of the middle chamber was 
the same as in the absolute measurements in water. In these measurements, as in the 
chambers’ angle dependence measurements, the electron density of PMMA, which is 
the material in the matrix, was not considered to be different to the electron density of 
water. The equivalent depth for 5.0 mm of PMMA is 5.9 mm layer of solid water 
[23][24]. The effect of this on the results can be analyzed by the measured percentage 
depth doses shown in image 12. At the depth of about 10 cm the doses decrease 0.38 
percentage units per mm by 6 MV and 0.28 percentage units per mm by 10 MV. The 
effect of this on the factor to make the matrix comparable to the absolute dosimetry is, 
however, only a couple of thousandths decrease. Also this kind of 0.9 mm error could 
occur during positioning of the measurement devices by the lasers. This is one reason 
why this was not taken into consideration for these investigations, but a more relevant 
one, is the difficulty to determine the exact equivalent depth in solid water in 
investigations of the measuring angle dependence of the matrix. Especially from the 
gantry angles, where from radiation traverses through the other ionization chambers of 
the matrix, the determination of the exact equivalent depth in water would have been 
impossible. Also investigations about the relation between the used energy and 
measuring angle dependence of the chambers should be investigated. However, the 
same kind of results, firstly about the matrix showing relatively more than absolute 
measurements, and secondly about the angle dependence of the chambers of the matrix, 
have been introduced also by other investigations [23]. 
 
 
6.1.2 Analyses of investigations concerning the factor for eliminating the 
effect of attenuation by the treatment table 
 
In the investigations measurements were made by intervals, which enabled 
determination of a factor for eliminating the effect of attenuation by the treatment table 
in all the variable shape areas of it. Using these values, and by the graph made out of 
these, it is also possible to determine a factor for different sizes of VMAT arcs. 
However, also these investigations were done only using the middle chamber of the 
matrix. The effect of the treatment table is obviously different, for example, to a 
chamber five centimetres laterally aside from the middle chamber. The convenience of 
the factor for other chambers can be discussed, but the similarity of the treatment table 
in both lateral directions might cause the overall effect to be about the same as the other 
chambers as to the middle chamber in cases, where the VMAT arc includes the whole 
interval of gantry angles from 110° to 250°. 
 
The effect of attenuation by the treatment table was investigated in order to determine a 
correction factor for the created verification system, but the results of the investigation 
make it also possible to analyze the effect of attenuation by the treatment table in actual 
patient treatment. The amount of the effect of attenuation by the treatment table 
increase along the traversed distance of radiation through the table. The measurement 
point in the investigations was 8.5 cm above the surface of the table, so for targets 
higher than that, the effect of the treatment table is smaller from the lateral sides of the 
table, and the amount of gantry angles, from which the treatment table is in between the 
radiation source and target, decrease. Concerning targets close to the table, the effects 
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are opposite. However, in the treatment of patients with bladder cancer, the targets are 
normally about 10 cm, or more, above the treatment table.  
 
 
6.1.3 Accuracy of the established calibration factor for the measured dose 
distributions 
 
In order to determine the calibration factor for dose distributions measured using the 
created VMAT treatment plan verification system, all the main effects were considered, 
which would disturb the reliability of the measured doses. The factors were determined 
by specific investigations, which involved considerations of the effects of different 
particular elements. During the investigations the goal to determine a calibration factor 
for VMAT treatment plans, which would be accurate enough for these purposes, was 
kept in mind, instead of digressing to concentrate on specifications of a certain feature 
in the measurement system. One reason for avoiding extremely precise investigations 
for a certain feature is the nature of the productions of VMAT treatment plans. The 
absorbed dose in a particular volume in matter might be produced only by radiation 
from certain directions even with a 360° arc. The calibration factor was determined at 
the middle chamber of the matrix by considering all the effects from all 360°, and 
averaging them to make it a generally functional estimation. For the measured doses 
using some chambers away from the middle chamber, the determined factor could be 
too inaccurate in cases where also the direction of radiation is only from the lateral to 
back direction, where the effect of attenuation by the treatment table and the angle 
dependence of the chambers have higher effects. However, it is more probable that the 
effects average each other out, and the calibration factor is relatively accurate enough in 
all areas of the volume, where the absorbed dose is high. In spite of all, it is important 
that the user keeps in mind these issues while analyzing the measured data, instead of 
drawing too hasty conclusions. 
 
 
6.1.4 Analyses of the measurements and calculations made with the created 
system 
 
From the results of these investigations and by the comparable graphs drawn by them, it 
is possible to visually analyse the effect of attenuation by the treatment table and the 
measuring angle dependence of the chambers of the matrix, but most of all to analyze 
the accuracy of the matrix as measuring device by comparing the measured doses with 
the calculated ones. Using the graphs, showed in image 15 in section 5.1.1, it is 
possible to perceive the shapes of the system and also to analyze the effects of the 
materials through which radiation traverses from different directions, and how these 
effect the graphs. So, also the properties of the calculation algorithms can be analyzed. 
 
The angle dependence of the chambers of the matrix can be perceived by comparing the 
graph of the measured doses and the one measured only from the gantry angle of 0° 
with a relative amount of solid water. This investigation proves the measuring angle 
dependence of the chambers, because the graph measured only from the gantry angle of 
0° with a relative amount of solid water is at the same overall level and by similar 
shapes with the calculated ones. However, the measured point doses using a gantry 
angle of 0° with a relative amount of solid water are larger than the calculated ones 
using the analytical anisotropic algorithm of Eclipse. This might be because there was 
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not set solid water in order to consider also the amount of PMMA from different 
directions. Anyway, the point doses calculated using the analytical anisotropic 
algorithm show less particularly in areas, where radiation has to traverse through the 
matrix and the chambers to get to the measuring point. From the investigations about 
making the chambers of the matrix comparable to the absolute dosimetry, it was shown 
that the chambers of the matrix measure a little more than the absolute chamber. This 
might also be a reason why the measured doses are a slightly higher than the calculated 
dose graphs. It is not the case with Monte Carlo algorithm of Monaco in all directions. 
The reason, why the calculated point doses by Monte Carlo are higher at some points 
than the measured ones, might be the capability of it to consider heterogeneities in 
matter, for example build ups, when radiation traverses from solid or liquid material 
into gas. Also in calculations using the Monte Carlo algorithm there are relatively large 
differences between point doses due to Monte Carlo variance. Due to these reasons also 
the accuracy of the user to record point doses in the right place from the calculated dose 
distributions is even more important with the Monte Carlo algorithm than with the 
analytical anisotropic algorithm. This can be seen also by larger changes in the graph of 
the Monte Carlo algorithm compared to the analytical anisotropic algorithm one in 
image 15. 
 
 
6.2 Analyses of the Ball Test 
 
6.2.1 Analyses of the comparisons between calculated plans 
 
By challenging the treatment planning system to optimize challenging cases as in the 
ball test, there was found limitations of the optimization module. These limits are 
obviously very dependent on the individual case, so the most noteworthy issue in this 
part of the test is that the system will be able to offer information about the infeasibility 
of the set parameters. However, the treatment planning system will not inform the user 
about any infeasibility in inserted parameters, if the targets are not failed very radically. 
Also as seen from tables 1 and 2 in section 5.2.1, the targets, or constraints, set by the 
user are not durable. Of course this is a matter of parameters, but here, however, the 
limits of the constraint doses were set as primary, and still the limits were crossed in all 
cases. This shows that the calculation system is battling between the inserted targets 
and constraints, and calculating compromises between these challenges, if all the goals 
and limitations are not reachable. 
 
By comparing the statistics of the calculated dose distributions of the ball test with 
tables 1 and 2, there are not significant differences in reached doses between energies 6 
and 10 MV in similar plans. However, small overall issues are noticeable. Using energy 
of 10 MV the target doses were reached in bigger volumes of the targets in most cases. 
This, however, meant a little bit higher hot-spots as well. Using energy of 6 MV the 
absorbed doses in the constraint volume were slightly smaller. In this kind of test, 
where the constraint is inside the target volume, these noticed issues were impending 
by the different properties of depth doses between the two photon energies. By paying 
attention especially to the tests where the dose limits of the constraint ball were not 
adjusted lower than the target dose, the treatment planning system were not able to 
produce an objective dose to the very sides of the target especially to the last CT slices. 
The reason for this cannot be too tight constraint outside the target ball, because these 
parameters did not challenge optimization at all. The reason, therefore, might be 
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unattainable for the user. There should be paid attention to the issue in the clinical 
treatment planning process. One effective way avoiding this could be by adding a target 
volume with about 2 mm wider margins in all directions than the actual PTV in the 
optimization. 
 
From a clinical point of view, the results of the tests slightly favour using energy of 10 
MV in the treatment planning of patients with bladder cancer, because with the use of 
10 MV energy, target doses were reached a little better. This effect will grow the deeper 
in matter the target is situated. In the pelvic area the distance to the bladder from the 
surface of the body is relatively greater than the distances with the created system. It 
seems by these investigations, that using smaller energy the absorbed doses in 
constraints could be kept slightly smaller, but however, this kind of challenging cases, 
where the constraint would be inside the target area, are not involved in the treatment of 
patients with bladder cancer. Obviously with higher energy the radiation which 
traverses through the target volume to organs at risk influence more these organs than 
with lower energy. However, with higher energy less monitor units are needed, and so 
the absorbed dose on the way to the target is smaller. In the actual treatment planning 
process of patients, the optimization parameters are adjusted suitable for each case by 
the user so that the target volume, organs at risk and interactions in matter with the used 
energy are taken into consideration.  
 
 
6.2.2 Analyses of the comparisons between calculated and measured dose 
distributions 
 
Analyses using the results of measurements made with the matrix 
 
There was no distinct way how the chambers, which measured doses that did not pass 
the accuracy limits, distributed in the matrix. However, in the high gradients, there were 
bigger differences overall in the accuracy of the measured and calculated point doses. 
In these areas the average differences were about 2 - 3 %, but in point doses at 
chambers in the constant dose area the average differences were usually 0 - 2 %. It was 
also possible to recognize from the profiles, that the gradients were slightly sharper in 
the calculated ones. However, this observation was done only in the outer gradients of 
the target ball, while the remainder of the dose distribution area acted very similarly 
between the calculated and measured ones. Therefore, the chambers which did not pass 
the accuracy limits of 3 mm and 3 % were positioned quite randomly in the dose 
distribution area. But as it is possible to compare percentages of the passed measuring 
points, it is noticeable that the percentage is higher when taking into account the 225 
most centrally located chambers. One reason for this might be in the calibration factor 
for measured dose distributions using the created system, because of the chambers’ 
dependence on the measuring angle. The factor was adjusted using the measurement 
results for the middle chamber, which was irradiated from all 360° of rotation. The 
chambers outside the target ball were not irradiated from the direction where their 
accuracy is at best, from in front. So, the further away from the target the inspected 
chamber is, the larger the correction factor should be for it. In addition, some of the 
calculation parameters might affect the accuracy of the calculated dose distribution. 
These parameters, however, were adjusted to be in the same scales as in treatment 
planning for bladder cancer patients. Furthermore, the Monte Carlo algorithm of 
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Monaco follows Poisson’s statistics which signifies that the point dose deviation gets 
smaller while absorbed dose gets higher. 
 
Even though all the measured treatment plans passed the accuracy objectives, it is 
noticeable that equivalence between the calculated and measured dose distributions 
becomes a little poorer in the plans which forced the treatment planning system to 
struggle close to its limits. This is possible to recognize by comparing the measured 
dose distribution of plan R3D66% to the one of plan R3D60% with both used energies 
shown in table 3 in section 5.2.2. This can be noticed also by letting the treatment 
planning system optimize the dose distribution without considering the constraint ball 
inside the target one, as in plan R3D100%, in which all of the point doses passed the 
limitations close to the target area with both energies. 
 
Repetitive measurements of dose distribution with plan R3D66% show that the 
accelerator is able to produce one plan after another accurately. It seems that the matrix 
had been about 1 mm in a different position after re-positioning. Possible positioning 
errors of about 1 mm, caused by the user while positioning the matrix using the lasers 
and field light, are worth taking into account while analyzing the results. 
 
 
Analyses using the results of measurements made with radiochromic film and the 
matrix together 
 
The most essential theme of the measurements by radiochromic film was the evaluation 
of the sharpness of gradients compared to the ones measured by the matrix. To make 
the evaluation more distinct, the measured profile graphs using the matrix are re-drawn 
in a different way. The middle points of the point doses measured by the chambers are 
connected to the next ones by graphs especially at the areas of gradients. These re-
drawn graphs are shown in images 28 and 29 using black lines. It can be observed that 
the matrix is not capable of showing exact shapes of the gradients especially in cases of 
very rapid changes in dose distribution. However, by concentrating the point doses at 
the measurement points of the chambers, it can be discovered that at these points the 
measured doses correlate very well with each other. The point doses correlate very well 
also in other measurement areas especially by taking into account the 0.5 cm difference 
in measuring levels. Actually the only area where there is significant error in dose can 
be observed in the high dose area in the profile in image 28. By observing the isodose 
of the film measurement shown in image 19 in section 5.2.2, it can be double-checked, 
that in the same area there is a very high dose area. By evaluating the equivalence 
between the dose distribution overall, this inconsistent dose area may have affected by 
the fragility and structural discrepancies of the film [22]. There is also noticeable rapid 
change in dose at the very end of the profile measured by the film shown in image 29. 
At that area the film was destroyed because there was drawing ink inserted by the user 
for the film positioning. However, the equivalence in dose distributions between the 
radiochromic film and the matrix measured together strengthens the observations of the 
suitability of the created verification system for reliable dose distribution 
measurements. 
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Image 28: Profiles of left to right directions of measured dose distributions of the plan R3D60%6MV. 
The red line signifies the measured dose profile by film, the green line the measured point doses using 
the chambers and the black line is connecting the middle points of the measured doses of each chamber. 
           
 
 
Image 29: Profiles of gantry to table directions of measured dose distributions of the plan R3D60%6MV. 
The red line signifies the measured dose profile by film, the green line the measured point doses by the 
chambers and the black line is connecting the middle points of the measured doses of each chamber. 
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6.3 Analyses of the VMAT treatment plan verifications with the 
created system 
 
All together there were 28 clinical VMAT treatment plans measured by the created 
verification system during the project. The goal that 95 % of the ionization chambers of 
the matrix should pass the accuracy limits of 3 % and 3 mm at least inside about the 
area of 50 % isodose was reached in almost all the plans. The plans that did not pass 
this limit had however at least 93.8 % passed point doses. It was noticeable that almost 
all the failed chambers were in the areas of high gradients. In these areas, the accuracy 
of the device cannot be absolutely trusted most of all because of the gaps between the 
chambers. It was also estimated, that the percentage of accepted point doses inside the 
area of  about 10 % isodose were almost as high as close to the target area. The failed 
point doses outside the target area had almost beyond exception smaller measured 
doses than the calculated ones. The reasons that measured doses were smaller relatively 
far away from the target area are probably the same as those discussed for the ball test. 
However, from a clinical point of view, it is more desirable that the measured doses 
outside the target volume are smaller than expected, rather than the other way around. 
 
Also by these clinical verification measurements, the calibration factors calculated for 
the VMAT treatment plan verification system seem to be correct. It was noticeable that 
within the treatment plans, which were measured also by the quality assurance mode 
without gantry rotation, the dose distributions areas where the accuracy limits were not 
reached correlated very well to the measurements done with gantry rotation. In 
addition, a concern that the common calibration factor for the measured dose 
distributions might be too strong for some chambers and too weak for some chambers, 
indicating to have been too strong. By investigating the areas of dose distributions, 
which did not pass the accuracy limits, there was not found evidence that the direction 
of radiation into the area would have been the cause for the inaccuracies. This was 
investigated by comparing the measurement results using the original plan to the ones 
using quality assurance mode without gantry rotation. In addition, it was investigated 
using the Monaco treatment planning system to analyze the plan segment by segment, 
in order to check are the absorbed doses in a certain irradiated volume from certain 
directions much higher than from the other directions. This way can be analysed have 
the correlation factors for eliminating the effect of attenuation by the treatment table 
and the angle dependence of the chambers been appropriate for some particular areas of 
chambers in each case. 
 
Using these experiences, it seems that the created verification system is a reliable tool 
for the VMAT treatment plan verification process. However, the long-term experiences 
and, furthermore, even more specific investigations using the system are desired in 
order to use only the created system in the VMAT treatment plan verification process. 
Especially the experiences on suitability of the common calibration factor for the 
measured dose distributions in the VMAT treatment plans, in the cases where small 
segments are used, and so the absorbed doses might include the irradiation only from 
particular directions, should be collected. 
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6.4 Analyses of the CBCT equipment in patient positioning 
 
Using the results of the investigations, it is possible to state that the CBCT equipment is 
suitable for the clinical use in patient positioning. The quality of the images was 
sufficient for visualizing the internal organs, the accuracy of the automatic matching 
with the grey-value algorithm was shown precise and the recommended movements 
using the CBCT system and the Hexapod treatment table were shown also accurate. In 
addition, the possibility to create imaging presets was introduced. The created presets 
were investigated in order to assure also their reliability in the clinical environment. 
Using the results, the presets Bladder A, B and C were introduced for the clinical use. 
 
 
6.4.1 Analyses of the automatic matching accuracy between the presets 
 
From the results of the automatic matching, done by using the CBCT images with the 
presets Prostate M10, Prostate M10 Fast and the created ones, the parameters of these 
presets not affected the accuracy of the automatic matching. The equivalence between 
the original ones indicates that by decreasing the number of the frames to 330 from 
660, and furthermore, the imaging time to 60 seconds, not affect the automatic 
matching accuracy even though visually the image quality suffers a little. Moreover, as 
long as the image quality is visually good enough for the clinical use, decreasing the 
tube voltage, current or time, do not affect the accuracy of the automatic matching. 
Using the manual re-matching, the adjustments done using the automatic matching 
were shown precise in all the cases with every preset. Using the manual matching, the 
matching was not possible to make as precisely or at least not as quickly, as using the 
automatic matching. 
 
 
6.4.2 Analyses of the irradiated doses using the presets and clinical 
significance of the results 
 
Using the created presets in imaging, the irradiated doses decreased comparing to the 
irradiated doses using the original presets, as it was desired. Using the created preset 
Bladder C, the absorbed dose in the maximum point on the surface of the phantom was 
less than 15 % of the dose using the preset Prostate M10 and less than 25 % of the dose 
using the preset Prostate M10 Fast. In practise, for example in the treatment of 35 
fractions, in which the CBCT imaging is performed before and after each fraction, 
using the created preset Bladder C, the absorbed dose in the maximum point on the 
surface is in total 0.315 Gy which is 2.184 Gy less than with the preset Prostate M10 
and 0.980 Gy less than with the preset Prostate M10 Fast. Using these numbers in 
analyses, it has to be kept in mind that the CT thorax phantom is not equivalent by 
shapes and matter with the patients, and that every patient is different by the body 
shapes. However, these results are suggestive. Furthermore, in order to use, for 
example, the preset Bladder C in imaging of a patient, the image quality has to be 
sufficient in the case. 
 
It can be discussed that how worthwhile it is to decrease the irradiated dose of the 
CBCT imaging, because the relation of the decrease is relatively small by comparing to 
the total treatment doses. However, one of the main goals in the radiation therapy is to 
be able to treat the target with the planned dose with as little absorbed dose as possible 
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in the other parts of the body. So, even small dose decrease in the healthy tissues is 
preferable. In the treatment of patients with bladder cancer the CBCT imaging before 
the treatments is essential, but the worth of the imaging always after the fractions can 
be discussed. With the absorbed dose caused by using the created preset Bladder C, the 
decision whether or not to perform CBCT imaging also after the fractions can be done 
easier. 
 
 
6.4.3 Accuracy and reliability of the automatic matching with grey-value 
algorithm 
 
From the results of the investigations which considered only one directional error at a 
time, it was noticed that all the recommended position corrections were not over than 
the exactitude of the setting accuracy of the phantom by the user. In addition, there was 
no differs in the accuracy of the recommendations between the smaller and bigger made 
up error in the same direction. With the setting accuracy of the phantom it is not 
possible to investigate the capability of the automatic matching algorithm with the 
minimum scale of the recommendations. However, this investigation was accurate 
enough to analyze the accuracy and reliability of the automatic matching in the 
significant scales for patient treatment, in which the automatic matching using grey-
value algorithm seems to work well. 
 
The exact realization of the position error in multiple directions was not even as precise 
as to one direction at a time. It was, however, also accurate enough to make possible 
analyses of the accuracy of the automatic matching in the significant scales for patient 
treatment. Using the 0.5 cm and 0.5° errors in four directions together, the position 
correction recommendation was reasonable by using the automatic matching. The result 
seemed precise using manual matching. In the case where the phantom was positioned 
2.0 cm in two of the translational directions and 2.0° in two of the rotational directions 
away from the isocenter, the recommendations using the automatic matching were 
obscure. However, using manual matching, the localization image was moved close to 
the exact position in the translational directions and then re-using automatic matching, 
the recommendations were more expected. The result seemed precise by reviewing the 
images. This case is shown in table 8. The results of the case indicate that the positions 
between the localization and reference images might have been too far from each other 
for the automatic matching algorithm. However, by this one obscure result in these 
investigations, it is not possible to claim a specific reason for the confusion in the 
automatic matching or to draw conclusions about uncertainty in the work of it. In order 
to do so, there should be done an extensive investigation and also get acquainted with 
the matching algorithm. Furthermore, in order to investigate the accuracies of the 
automatic matching precisely in submillimetre scale the phantom should be attached to 
a micrometer adjustment device the way it would not disturb the imaging. In addition, 
even though the box of expanded polystyrene is suitable for keeping the interior stable, 
the material of the box is a little soft outside, which might lead to inaccuracies while 
adjusting the phantom repeatedly. However, using the results of these investigations, 
even though the automatic matching worked precisely in all the other parts of the 
investigations, it is reasonable to recommend reviewing the results of the automatic 
matching manually before performing the position corrections and delivering the 
treatment of patients. 
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Table 8: Recommendations using the automatic matching before and after manual adjustments in the 
case of set error of 2.0 cm in two of the translational directions and by 2.0° in two of the rotational ones. 
 
Directions of the 
displacement 
The size of the 
displacement 
The size of the 
recommendation 
The size of the 
recommendation 
after manual 
adjustment 
tx, ty, rx and rz 
tx = 2.00 cm   rx = 2.0°
ty = 2.00 cm   ry = 0.0°
tz = 0.00 cm   rz = 2.0° 
tx = 2.12 cm  rx = 2.6°
ty = 1.08 cm ry = 346.9°
tz = 0.92 cm   rz = 5.5° 
 tx = 2.02 cm  rx = 2.2° 
 ty = 1.89 cm  ry = 0.1° 
 tz = 0.00 cm   rz = 1.8° 
 
 
6.4.4 Reliability of positioning accuracy of Hexapod treatment table using 
the CBCT system 
 
In four of the five cases the recommendations for the patient repositioning were not 
more than 0.02 cm or 0.2° as shown in table 7 in section 5.4.3. Even though these 
recommendations are one step higher than the steps of the scale, they are not alarming, 
because the size of the recommendations did occur only to one direction out of six in a 
case. Moreover, those sizes of errors in the patient positioning are clinically 
insignificant. However, the bigger position recommendations in one case are a little 
concerning. The recommendations of 0.03 cm and 0.07 cm in two of the translational 
directions are not yet alarming clinically, but the error of 0.8° in target position is 
clinically undesired especially in cases, where organs at risk are next to the PTV. The 
position error was noticeable using manual matching after using the automatic 
matching with the first CBCT images. Also the recommendations which the software 
did suggest after using automatic matching with the second CBCT images indicate that 
the fault of the error was caused by the automatic matching instead of the system 
controlling movements of the Hexapod treatment table. Using this investigation, there 
is no reason to make alarming conclusions about the unreliability of the algorithm of 
the automatic matching. However, also using these investigations, it is recommended to 
double-check manually the result of the automatic matching. And even though the 
movement of the treatment table was shown clinically accurate using this investigation, 
it is also recommended to follow the treatment table realizing the desired movements. 
 
 
6.5 Analyses of the technical aspects of radiation therapy of patients 
with bladder cancer using the first clinical experiences with the 
introduced equipment and instructions 
 
6.5.1 Suitability of the instructions 
 
The work-flow of the complete treatment process was suitable with all the five bladder 
cancer patients. Each part of the process was realized essentially similarly, and the 
treatment of patients were delivered as planned. There were, however, special features 
in the individual cases, which make it reasonable to analyze the possibilities for some 
alternatives in the work-flow and suggest possible improvements for the future. 
 
In two cases there were not big changes in the bladder volume or shape between the 
four planning CT images. In these kinds of cases the CT images could be analyzed after 
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three CT images, and if there is not relatively large shape changes in the bladder, the 
fourth image could be performed after a longer period of time. However, because the 
patients are instructed to urinate just before every fraction, in these two cases as in all 
of the five, the volumes of the bladders during the treatment were not larger than the 
largest PTVs.  
 
The work-flow of the treatment planning and the parameters used in the Monaco 
treatment planning system were suitable with the five patients in the ranges introduced 
in the template. Using these experiences it seems that with 10 MV photon energy it is 
possible to reach better dose coverage in the PTV while minimizing the absorbed dose 
in organs at risk comparing to the use of 6 MV photon energy.  The values of the other 
parameters are, however, important to consider individually in every case and 
concentrate on evaluating and affecting the optimization in each case. In the cases 
where it was not necessary to achieve planned dose in the edges of the PTV, the dose 
limits of the constraints could be set very strict in the optimization. But in the cases 
where the full dose coverage of the PTV was necessary, like in the one shown in image 
22 in section 5.5, using an extra contour with margins of two millimetres around PTV 
assured the dose coverage also in the edges of the PTV. The extra contours could be 
also created for constraints, and use them in the optimization in order to try to minimize 
the absorbed dose in organs at risk. For example in the partial bladder cases the healthy 
part of the bladder wall could be contoured and set as a constraint instead of setting the 
complete bladder except the part in PTV as a constraint like in the first clinical cases. 
This could be done because large part of the bladder is urine which is not relevant to try 
to protect, but the protection of it challenges the optimization in vain. Furthermore, the 
individual shapes and sizes of the patients are worth to consider in the treatment 
planning. One of the five patients was obese, which made it more challenging to 
produce sufficient dose distribution in the PTV, and the limits of the absorbed doses in 
the constraints had to be loosened, and the treatment time was forced to be extended. In 
these kinds of cases with the 15 MV photon energy, which is going to be configured for 
the clinical use in the near future, it might be possible to achieve the planned doses in 
PTV easier. On the other hand, with increasing the used energy to 15 MV in the VMAT 
treatment plans, it might raise the amount of neutrons so high that the absorbed doses in 
the organs at risk might rise too much. 
 
The image quality of the CBCT images made possible to detect the shape and position 
of the bladder. Using the introduced work-flow, it was suitable to determine 
individually appropriate imaging preset for every patient. For two of the patients the 
quality of the images performed using the preset Bladder C was sufficient. That preset 
was used in imaging also after the fractions with the patients as well with other two 
ones. However, with these two patients the quality of the images performed using the 
preset Bladder A was sufficient for the patient positioning. With these two patients the 
used preset before the fractions were changed to the preset Bladder B after 10 fractions 
with one and 15 with the other, because decrease of the lipiodol volume reduced 
artefacts in the images. Using this observation, and by considering the image quality 
which provides the reliable visualization of the bladder wall, it is possible to question 
the use of the lipiodol in the complete bladder cases. In the partial bladder cases the use 
of the lipiodol is still worthwhile in order to determine the exact place of the tumour 
using the CBCT imaging. With the obese patient the image quality was good enough 
for the reliable bladder localization only using the preset Prostate M10. Therefore, with 
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the patient the imaging after the fractions was made only after first five fractions and 
after that only once a week using the preset Prostate M10 Fast. 
 
The patient positioning using the automatic matching with the grey-value algorithm 
was precise almost exceptionally, and the capability to use also the rotational position 
corrections was observed useful. However, there were randomly situations where the 
results of the automatic matching were not correct. Most of these times the obscure 
recommendation of the software was easily noticeable, because the localization image 
was not set even close to the reference one. In these cases there was either relatively 
large change in the volume of the rectum or displacements in the bladder and the 
closest bowels next to it compared to the situations in the reference image. In these 
cases the matching was made manually. Using these experiences, it is recommended to 
review the results of the automatic matching, and also to consider the size and place of 
the automatic matching volume in each case. 
 
 
6.5.2 Analyses of the clinical experiences with the introduced equipment and 
comparisons between these to experiences with previously used equipment  
 
One of the novelties introduced using the new linear accelerator for the treatment of 
patients with bladder cancer in HUCH was the capability of the VMAT. Even though 
the treatment planning of the VMAT is realized with the inverse planning as in the 
IMRT, the possible advantages of realizing the treatment with a single arc and using the 
biological optimization with the Monaco treatment planning system were analyzed. 
Furthermore, the possibility for the patient positioning in the six degrees of freedom 
was introduced, and the first clinical experiences were gathered. As with the previous 
treatment method, the CBCT imaging was used for the on-line localization of the 
bladder. However, the benefits of the CBCT system of Xvi are also discussed in this 
section. 
 
The treatment planning using the biological optimization with the treatment planning 
system Monaco was considered practical especially because of the constant interaction 
between the software and the user during the optimization. The possibilities to set the 
organs as serial or parallel by their biological properties and to define the tolerance of 
the organs for irradiation were also considered advantageous. However, it is the formed 
dose distribution and especially the reliability of it to be delivered as calculated, which 
matters in the end. In order to evaluate the dose distributions calculated using the 
introduced treatment planning strategies, also three of the cases were planned with the 
previously used methods and equipment which are introduced in section 2.2. Two of 
the cases were partial bladder ones using 6 MV energy in the VMAT treatment plans. 
One of these cases is shown in image 30. In the third case the complete bladder was 
treated using 10 MV photon energy in the VMAT treatment plan. The dose 
distributions of each case were analyzed using isodoses and DVHs. The attention was 
focused on the 95 % isodose coverage in the PTV compared to the absorbed doses in 
the rectum, the bowels, the hip bones, the parts of the bladder outside the PTV and the 
body. In the partial bladder cases the dose coverage in the PTV were about 2 % less in 
the VMAT treatment plans with 97 – 98 % coverage. In the complete bladder case the 
PTV dose coverage was 100 % in the VMAT treatment plan, but about 2 % less in the 
IMRT treatment plan. However, in all the treatment plans the average absorbed doses in 
all of the organs at risk were at least a little less in the VMAT treatment plans. Using 
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these evaluations, it seems that with the biological optimization and the use of the 
VMAT, it is possible to reduce the irradiated volumes of the organs at risk, with 
acceptable PTV dose coverage. Furthermore, the overall irradiated volumes of the body 
were less in all the cases. Also with comparing the dose distributions, it was noticeable 
that the gradients were sharper in most of the directions. These evaluations were done 
with comparing for example the 80 % isodoses. In addition, the irradiated small dose 
volume of body seems to be smaller by the VMAT treatment planning, which can be 
evaluated with comparing, for example, the 20 % isodoses. Also these observations can 
be seen in image 30. The results of the investigations, which indicate that the Monte 
Carlo dose calculation is even more accurate than the calculations made using kernel 
based methods especially in the heterogeneous volumes, support relying on these 
observations [15]. However, it is rather challenging to analyze the treatment plans made 
using two softwares with different calculation algorithms. Also the experience of the 
user to use the equipment might have influenced to the resulted outcomes. Therefore, 
there should be more investigations done and experiences gathered, and also consider 
the equivalence between the calculated and delivered dose distributions using both of 
the systems, before stating these evaluations authentic.  
 
 
     
 
  
 
Image 30: The same partial bladder case planned using Monaco with VMAT (on top) and using Eclipse 
with IMRT (under). In both of the treatment plans the isodoses are represented with the same colours; 
dark red is 107 %, green 95 %, turquoise blue 80 %, blue 50 % and dark blue 20 %. In both of the DVHs 
yellow indicates the PTV, violet the bladder, turquoise blue the rectum, red the bowels, dark blue the hip 
bones and green the body. 
 
The total treatment time including the patient positioning with the six degrees of 
freedom and the CBCT imaging also after the treatment was almost without exceptions 
20 – 25 minutes, which is the same as with the treatment using the previous method in 
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HUCH. The patient positioning using the Hexapod treatment table was found practical 
and beneficial especially because the rotational corrections were required as often as 
the translational ones in these first five bladder cancer cases with the introduced 
equipment. In addition, the possibility to perform the CBCT imaging also after the 
fractions with relatively good image quality enough without significant extra irradiated 
dose can help following the treatment with determining the movements of the organs 
during a fraction, and so to contemplate possible improvements for the target planning. 
With the previous method the dose delivery time was five minutes by average, so using 
single arc there is no profit in the treatment time with these clinical experiences. 
However, with a single arc the delivery time is constant, because the working paces of 
the radiographers do not matter as much in the realization of a VMAT treatment plan as 
in the delivery of seven IMRT fields. The average amount of monitor units decreased 
from about 1000 - 1100 monitor units irradiated with the IMRT treatment plans to 700 
– 900 monitor units irradiated with the VMAT treatment plans. [7] 
 
With comparing the performance of the CBCT system of Xvi to the previously used 
CBCT system of OBI in treatment of patients with bladder cancer, there are noticeable 
improvements in the image quality, but also in the possibility to decrease the irradiated 
dose of the imaging. The OBI system was used with two different settings for the 
imaging of bladder cancer patients, which both performed the imaging in about 60 
seconds. The decision about which one to be used in the imaging have been made with 
the quality of the images performed in the individual cases. Using the results of the 
dose measurements made in HUCH in 2009 with a CT head phantom and measuring 
also the absorbed doses using the introduced presets of Xvi with the same phantom, it is 
possible to compare the irradiated doses produced by the CBCT imaging with the two 
systems. The results of the measurements are shown in table 9. Using these results, it is 
possible to calculate that with one of the settings, named here as Setting A, of OBI the 
irradiated dose is a little less than with the preset Prostate M10 of Xvi, and with the 
other setting, named here as Setting B, of OBI the dose is approximately the same as 
with the preset Prostate M10 Fast. The irradiated dose with the preset Bladder C in Xvi 
is about 25 % of the irradiated dose using Setting B of OBI. In the CBCT images of the 
OBI the field of view is larger, and so is the irradiated volume of the body. The image 
quality was significantly better in the CBCT images performed using the original 
presets of the Xvi than with the settings used in the OBI, especially if considering the 
visibility of the intestines. Also in cases where the rectum or bowels contain a lot of 
gas, the quality of the CBCT images performed with the OBI suffer strong artefacts, 
which have not noticed to be a problem with the Xvi.  In the image 31 is shown a 
CBCT image performed using Setting A of the OBI. It can be compared with the 
images 23 - 27 shown in section 5.5, in which there are shown images performed with 
the presets of the Xvi used in the bladder cases with the same size of a patient as in 
image 31. 
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Table 9: The measured irradiated doses with the CT head phantom in the middle and on the surface of the 
phantom using three presets of the Xvi and two settings of the OBI used in bladder cases in HUCH. 
 
Preset or Setting: Dose at Isocenter (mGy) Dose on surface (mGy) 
Prostate M10 / Xvi 65.0 67.5 
Prostate M10 Fast / Xvi 33.5 35.2 
Bladder C / Xvi 8.5 9.0 
Setting A / OBI 52.0 55.0 
Setting B / OBI 33.0 37.0 
 
 
  
 
 Image 31: Coronal view of a CBCT image performed using Setting A of the OBI. 
 
 
7 Conclusions 
 
All the goals of the project were reached. The verification system for the VMAT 
treatment plans was created, and it was found to be a reliable and suitable tool for the 
dose distribution measurements. Using the created system, the equivalence between the 
calculated VMAT treatment plans with the treatment planning system Monaco and the 
delivered plans with the linear accelerator Elekta Axesse were configured using the 
photon energies of 6 and 10 MV. The new presets were created for the CBCT imaging, 
which were found to be clinically worthwhile by their capability to perform high 
quality images with relatively small irradiated doses. The operations of the CBCT 
system with the Hexapod treatment table were determined precise as well with the 
created presets as the original ones. In addition, the suitable template for the VMAT 
treatment planning using Monaco treatment planning system was introduced. Using the 
results of the investigations on introduced equipment, the instructions for the radiation 
therapy process of patients with bladder cancer; including the strategies for VMAT 
treatment planning, CBCT imaging and patient positioning, were created. 
 
During the project the experiences of daily clinical work were gathered. There came up 
several issues related on working with the equipment, which had to be solved. Using 
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the solutions and experiences, clinical work with the equipment became more practical. 
For example, instructions in order to use the Hexapod treatment table and the CBCT 
system overall were introduced in HUCH. Using the experiences of creating the 
imaging presets in the Xvi, new presets for clinical use with the other cases as well 
were considered. For example, new presets were created also for imaging the prostate 
carcinoma patients which have gold seeds inserted in the prostate. Based on the preset 
Prostate Seed, the new presets were created to perform images, in which also the walls 
of the prostate are clearly visible without exposing the patient for greater amount of 
radiation. Furthermore, the experiences gathered during the project of the work with the 
treatment planning system Monaco were shared in the clinic, and used for improving 
the planning strategies also for the treatment of patients with other carcinomas.  
 
The results of the investigations during the project construct strong basis for some 
further investigations. The investigations done in order to create the verification system 
for VMAT treatment plans could be continued in extremely precise level. Instead of 
using the calibration factor for the complete measured dose distribution, the calibration 
factors could be defined individually for the measured point doses in particular 
situations. It is not possible, however, to insert different calibration factors for each 
chamber of the matrix, but with the pre-determined factors for the different situations 
and with examining the dose distribution, the analyses of the dose distributions could 
be made specifically for the different point doses. In addition, the effect of attenuation 
by the treatment table could be investigated using various measuring points above the 
treatment table in order to evaluate the effects in different kinds of treatments. 
Furthermore, it would be beneficial to investigate the function accuracy of the CBCT 
system, especially using the automatic matching, in depth. In those investigations 
should be concentrated also on the operational principles of the automatic matching 
algorithms in order to develop them instead of just examining their performance in 
different cases. The created internal organ phantom was discovered suitable for the 
CBCT investigations. However, in order to use the phantom in very specific 
investigations on the CBCT system repositioning accuracy with the Hexapod treatment 
table the capability of positioning it by the user should be able to be done reliably and 
extremely accurately. Moreover, it is desirable to reduce the treatment times of the 
treatment of patients with bladder cancer. Using the treatment planning system 
Monaco, the users should gather the experiences and try to focus on finding the suitable 
parameters for the optimization in order to decrease the treatment times while 
maintaining the qualities of the dose distributions. In addition, the treatment of the first 
five patients with bladder cancer using the equipment could be analyzed more 
precisely. The quality of the CBCT images performed using the Xvi make possible to 
reconstruct the actually delivered dose distributions with the treatment planning system 
Monaco. For example, the irradiated volume of the bowels could be calculated. Using 
the data, the benefits of using the equipment in treatment of bladder cancer patients 
could be analyzed by comparing the data with the ones calculated from the treatment of 
bladder cancer patients with the previously used equipment in HUCH by Tuomikoski et 
al [7]. The CBCT images which were performed after the fractions could be also taken 
into the analyses. Using those images, it could be investigated is there some sort of 
statistical changes in the bladder volume and shape during the fractions. Moreover, 
using the CBCT images, it could be reconsidered sufficient margins for the PTV in the 
treatment of bladder cancer patients with the new treatment unit. 
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In the near future also the 15 MV photon energy of Elekta Axesse is going to be 
introduced for the clinical use. The configuration process can be done using the created 
verification system with the introduced work-flow. Furthermore, the verification system 
can be adjusted for the dose distribution measurements with the other linear 
accelerators as well. This could be beneficial especially if the prospective new 
accelerators for HUCH in couple of years are capable for VMAT. It is also interesting 
to receive new versions of the used equipment. For example, there are high 
expectations that using the expected new version of Monaco treatment planning system 
it is possible to plan the treatment of patients even more practically. However, the work 
using the introduced equipment is in the very beginning of their life cycles. The 
experiences of the users with the introduced equipment and methods in the radiation 
therapy of patients with bladder cancer are essential to be gathered in the long run in 
order to keep the wheels of improvements running.    
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Appendix A 
 
The instructions for the radiation therapy process of the bladder cancer patients in 
Helsinki University Central Hospital. Department of Oncology, HUCH. 
 
HEL S I N GI N  J A  U UD E N M A A N  S A I RA A NH O IT O P I I R I   
HEL S I N GF ORS OCH NYL ANDS SJ UK V ÅRDSDIS TRI KT   
 
HYKS,  Syöpätautien klinikka                                 12.5.2011 
 
Ohje:  ANRAKKO_IGART.1                                                        Vastuuhenkilöt: Jani Keyriläinen ja    
 
Virtsarakkosyövän kuvantaohjattu adaptiivinen sädehoito (IGART) 
 
Tässä ohjeessa esitettävää hoitotekniikkaa käytetään T2-T4aN0 -virtsarakkosyövän 
kuvantaohjatussa adaptiivisessa sädehoidossa (IGART = image-guided adaptive radiotherapy) 
potilailla, jotka eivät sovellu kystektomiaan. Sädehoitoa edeltävinä tutkimuksina on virtsarakon MRI 
ja/tai varjoainetehosteinen TT. Lisätutkimuksina voidaan käyttää kystoskopiaa ja lipiodol-
merkkausta niihin soveltuville potilaille. Annossuunnittelu-TT (TTA) suoritetaan natiivikuvauksena 
0, 20, 40 ja 60 minuuttia virtsarakon tyhjennyksestä (miktion jälkeen potilaalle juotetaan 8 dl vettä). 
TT-simulointi (TT-SIM) suoritetaan 1. TTA-kuvauksen yhteydessä. Virtsarakon seinämään voidaan 
kuvantaohjausta varten implantoida röntgenpositiivista merkkiainetta (lipiodol) rakon päivittäisen 
paikantamisen helpottamiseksi kartiokeilakuvauksessa (CBCT:ssä). Tästä johtuen voidaan 
ohjeessa kuvattua tekniikkaa soveltaa ainoastaan kiihdyttimessä, joka on varustettu CBCT-
laitteistolla. Linac 3:ssa hoidettavien potilaiden IMRT-hoidon suunnittelu ja toteutus on esitetty 
kohdassa A). Linac 6:ssa hoidettavien potilaiden VMAT-hoidon suunnittelu ja toteutus on esitetty 
kohdassa B).  
 
Kohdealueet: 
 
PTV 1 (punainen): Virtsarakko 1 + marginaali 
PTV 2 (sininen): Virtsarakko 2 + marginaali 
PTV 3 (vihreä): Virtsarakko 3 + marginaali  
PTV 4 (keltainen): Virtsarakko 4 + marginaali 
 
Mahdollisten booster-suunnitelmien kohdealueet: 
 
PTV Booster 1 (punainen): Booster-alue 1 + marginaali 
PTV Booster 2 (sininen): Booster-alue 2 + marginaali 
PTV Booster 3 (vihreä): Booster-alue 3 + marginaali 
PTV Booster 4 (keltainen): Booster-alue 4 + marginaali 
 
 
Kriittiset rakenteet: 
 
Kolmiulotteinen rajaus, annosjakaumatarkastelu sekä annostilavuushistogrammit: 
 -  mahdollinen virtsarakon säästettävä osa 
 -  peräsuoli 
 -  suolisto (Bowels Segment & Intestinal Cavity) 
 -  lonkkanivelet 
   
Tyypillisiä fraktiointeja: 
  
PTV1-4:            yhteensä 25 x 1,8 Gy, 5 fr./viikko 
PTV booster 1-4: yhteensä 10 x 2,0 Gy, 5 fr./viikko. Kokonaisannos:65 Gy 
 
 
PTV1-4:            yhteensä 22 x 2,0 Gy, 5 fr./viikko 
PTV booster 1-4: yhteensä 10 x 2,0 Gy, 5 fr./viikko. Kokonaisannos:64 Gy 
 
PTV1-4:            yhteensä 21 x 2,5 Gy, 5 fr./viikko. Kokonaisannos:52,5 Gy 
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A) Linac 3  
 
IMRT-suunnittelu Eclipse:llä 
 
Suunnittelussa huomioitavaa: 
 
a) CBCT-kuvausta varten kannattaa luoda oma hoitojakso (course; esim. ”CBCT”). Siinä TT-SIM:n 
isosentripisteeseen lisätään suunnitelma ”CBCT”, joka koostuu asetuskentästä ja teknisistä syistä 
lisättävästä hoitokentästä. Hoitokenttää ei kuitenkaan todellisuudessa tule koskaan hoitaa, ja sen 
annokseksi asetetaan pieni luku (esim. 0,01Gy ≅ 1 MU). 
 
 
b) Todellisia hoitokenttiä varten luodaan oma hoitojakso (course; esim. ”IGART”). Siinä TT-SIM:n 
isosentripisteeseen tehdään neljä suunnitelmaa ”RAKKO_punainen”, ”RAKKO_sininen” jne., joita 
käytetään virtsarakon päivittäinen täyttöaste huomioiden. 
  
Kenttäjärjestely: 
 Potilas selällään 
Isosentripiste TT-SIM:n mukaisesti: Pituus:          PTV:n keskellä 
   Leveys:         Keskilinja 
   Korkeus:       PTV:n keskellä 
Energia: 6 – 15 MV. 
Kenttäkoko: PTV#+0.6 cm. 
Suojat: PTV#+0.6 cm, outside. 
 
Virtsarakkosyövän sädehoidon suunnittelussa voidaan tilanteesta riippuen käyttää joko FIMRT- tai 
IMRT-tekniikkaa. Hoitotekniikan valinnassa voidaan soveltaa seuraavia ohjeita: ”Prostatan 
sädehoidon annossuunnittelu” ja ”Lantion alueen IMRT-hoidot”. Mikäli hoitotekniikan valinnassa 
päädytään IMRT-hoitoon, yleensä 5-7 kenttää (ei kuvauskenttiä) tuottaa sopivan annosjakauman. 
Tällöin kenttäjärjestely voi olla esim. seuraavanlainen: 
  
Alkuosa: 25 x 1.8 Gy, PTVa-d: 100% ≙ 1.8 Gy 
7 IMRT-kenttää (6 MV): 
 
Kenttä Kanturi Keilanrajain Annoskertymäalueet 
1 DEX -takaviisto 230° 0° tai 90° PTVrakko, PTVboost 
2 DEX-viisto 265° 0° tai 90° PTVrakko, PTVboost 
3 DEX-etuviisto 325° 0° tai 90° PTVrakko, PTVboost 
4 AP 0° 0° tai 90° PTVrakko, PTVboost 
5 SIN-etuviisto 35° 0° tai 90° PTVrakko, PTVboost 
6 SIN-viisto 95° 0° tai 90° PTVrakko, PTVboost 
7 SIN-takaviisto 130° 0° tai 90° PTVrakko, PTVboost 
 
Loppuosan suunnitelmat (booster yhteensä 10 x 2 Gy, PTVe-h: 100% ≙ 2 Gy) tehdään 
vastaavalla menetelmällä kohdealueisiin PTVe, PTVf, PTVg ja PTVh. CBCT-kuvaus on erillisessä 
hoitojaksossa, ja hoitokenttien hoitojaksossa TT-SIM:n isosentripisteeseen tehdään neljä 
suunnitelmaa ”BOOSTER_punainen”, ”BOOSTER_sininen” jne., joita käytetään virtsarakon 
päivittäinen täyttöaste huomioiden. 
Hoito: virtsarakko tyhjänä 
Hoito: 1h virtsarakon tyhjennys + 6dl vettä / kemosädehoidon nesteytys 
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B) Linac 6 
 
VMAT-suunnittelu Monaco:lla 
 
Ennen suunnittelun aloittamista: 
  
 - Tarkasta, että struktuurit ovat siirtyneet Monaco:on oikeilla nimillään.   
 - Tarkasta, että struktuurit (BS&IC) on piirretty korkeintaan pari cm etäisyydelle      
    kraniaalisesti suurimmasta PTV:stä. Jos ei, poista kraniaaliset osuudet rakenteista.
 - Muokkaa struktuurien värit, etenkin PTV:t edellä mainittujen ohjeiden mukaisiksi.
 - Luo optimoinnissa käytettävät PTV:t 
  -> CT-tilassa: Contouring -> Auto Margin, nimeä OptPTVx, joka  
      muodostuu lisäämällä 2 mm marginaali kaikkiin suuntiin PTVx:stä. 
 
Suunnittelu: 
 
 - Luodessa uuden suunnitelman, valitse IMRT ja seuraavassa vaiheessa toisen    
   kierroksen laskenta-algoritmiksi Monte Carlo. Käytössä myös template:ja.    
   Alla esitetty suunnitelma Monaco:ssa Template:na nimellä: ”RakkoVMAT360”. 
 - Tarkista isosentri. Huomioi, että isosentrin on oltava paikassa, joka mahdollistaa 
   suurimmankin PTV:n mahtumisen kenttäkokoon (16*21cm) kaikissa hoitosuunnissa. 
   
                             
        Kuva 1: Beam Setup                    Kuva 2: Segment Shape Properties 
 
Beam Setup (Kuva 1), huomioitavaa: 
 - Nimeä kenttä PTV:n mukaisesti, esim. PTV1:lle kentän nimeksi 1A. PTV2:lle 1B jne.
 - Energia: 10x (Machine: L6-F10) 
 - Kollimaattorikulmaksi 0°, kunhan kattaa PTV:n kaikista suunnista. 
 - 360° VMAT, Increment:iä ei kannata pienentää alle 30°. 
 
Segment Shape Properties (Kuva 2), huomioitavaa:  
 - ÄLÄ MUUTA: ”Max. # of Shape Changes = 1”, “Min. Segment Size = 2” ja “Segment 
        Suppression Factor = 2” 
 - “Smooth”: 5 (Monaco 2.04 versiossa Medium). Pienentäminen ei paranna juurikaan 
    annosjakauman tarkkuutta, mutta segmenttien määrä kasvaa ja hoitoaika pitenee.  
    Smooth:n suurentaminen huonontaa selkeästi annosjakaumaa. 
 - ”Min. MU/Segment” ja ”Min.Dose Rate” väliltä 5-7. Pienentäminen: Tarkempi    
    jakauma, mutta pidempi aika. Suurentaminen: Heikompi annosjakauma, mutta 
    nopeampi hoidon toteutus. 
                                                                                                             Juha Korhonen 
Voimassa 31.12.2011 saakka                                                     Hyväksyjä:  Mikko Tenhunen 
 
HEL S I N GI N  J A  U UD E N M A A N  S A I RA A NH O IT O P I I R I   
HEL S I N GF ORS OCH NYL ANDS SJ UK V ÅRDSDIS TRI KT   
 
HYKS,  Syöpätautien klinikka                                 12.5.2011 
 
Ohje:  ANRAKKO_IGART.1                                                        Vastuuhenkilöt: Jani Keyriläinen ja    
       
               Kuva 3: IMRT Calculation Properties 
 
IMRT Calculation Properties (Kuva 3), huomioitavaa: 
 - ”Grid Spacing” ja ”Beamlet Width” arvot on oltava samoja. Aseta myös DVH-     
    properties -> ”Grid Size”:n arvo samaksi (Max. 1mm eri). 
  Huom! ”Prescription” -> ”....Complication Models” -> ”Shrink Margin” 
  toimii vain ”Grid Spacing”:n arvon monikertoina. Eli tässä tapauksessa 
  “shrink Margin” toimii arvoilla: 0.0, 0.3, 0.6, 0.9 etc. 
 
 
                                 Kuva 4: Prescription 
 
Prescription (Kuva 4), huomioitavaa: 
 - Jos Rectum:ssa (tai suolistossa) on reilusti ilmaa PTV:n alueella, kannattaa asettaa 
    ainakin PTV:n tai jopa kyseisten ilmaa sisältävien struktuurien ”Minimum Electron 
    Density”: 0. 
 
 - PTV:t -> ”Poisson Statistics Cell Kill Model” -> “Cell Sensitivity”: 0.75. 
  -> “Quadratic Overdose Penalty:” target-annos + 0.5 – 0.8 Gy 
  -> “Isoconstraint”: 0.600 – 1.000 
   -> Voi asettaa todella tiukoiksi etenkin pienille PTV:ille.
                       -> vähentää sekä hot- että cold-spot:ja. 
  
 - Rectum: Kun osittain PTV.ssä tai sen välittömässä läheisyydessä: 
                                                                                                             Juha Korhonen 
Voimassa 31.12.2011 saakka                                                     Hyväksyjä:  Mikko Tenhunen 
 
HEL S I N GI N  J A  U UD E N M A A N  S A I RA A NH O IT O P I I R I   
HEL S I N GF ORS OCH NYL ANDS SJ UK V ÅRDSDIS TRI KT   
 
HYKS,  Syöpätautien klinikka                                 12.5.2011 
 
Ohje:  ANRAKKO_IGART.1                                                        Vastuuhenkilöt: Jani Keyriläinen ja    
                 -> 1. “Serial...” -> “Isoconstraint”: noin 0,95 * target-annos 
                    -> ”k”: 12 
                    -> Klikkaa: ”Optimize Over All Voxels”                 
                -> 2. “Serial...” -> “Isoconstraint”: noin 0,5 * target-annos 
                    -> ”k”: 10   
                    -> “Shrink Margin”: 0,6 cm 
                -> “Parallel...” -> “Ref.Dose”: noin 0,65 * target-annos 
                    -> ”k”: 3 
                    -> “Shrink Margin”: 0,6 cm 
  
 - Rectum: Kun kauempana PTV:stä (esim. rakon anteriorisen seinämän hoito): 
               Rectumin paikka ”Prescription:ssa” vasta rakon ja BS jälkeen. 
  -> “Serial...” -> “Isoconstraint”: noin 0,5 * target-annos 
                    -> ”k”: 10 
                  
 - Rakko: Kun hoidetaan koko rakko, ei laiteta rakon struktuuria ”prescription:iin”. 
               Kun hoidetaan osa rakosta: 
  -> “Serial...” -> “Isoconstraint”: noin 0,5 * target-annos 
                    -> ”k”: 8                      
                                  -> “Shrink Margin”: 0,6 cm 
                      -> “Parallel...” -> “Ref.Dose”: noin 0,65 * target-annos 
                    -> ”k”: 2.5 
                    -> “Shrink Margin”: 0,6 cm 
 
 - BS:  -> 1. “Serial...” -> “Isoconstraint”: noin 0,95 * target-annos 
                    -> ”k”: 10 
                    -> Klikkaa: ”Optimize Over All Voxels”                 
                -> 2. “Serial...” -> “Isoconstraint”: noin 0,5 * target-annos 
                    -> ”k”: 1 (Joissain tapauksissa toimii hyvin k=10) 
                    -> “Shrink Margin”: 0,6 cm 
                -> “Parallel...” -> “Ref.Dose”: noin 0,65 * target-annos 
                   -> ”k”: 2.5 
  
 IC: -> “Serial...” -> “Isoconstraint”: noin 0,65 * target-annos 
                    -> ”k”: 1 (Joissain tapauksissa toimii hyvin k=10) 
                    -> “Shrink Margin”: 0,6 cm 
 
 Body: -> “Quadratic Overdose Penalty:” noin 0,7 * target-annos 
  -> “Isoconstraint”: 1.000 
  -> “Shrink Margin”: 0,9 cm 
 
Optimointi: 
 
 - 1. Kierros (Pencil Beam): 
  -> Mallaile parametreja niin, että algoritmi joutuu haasteisiin, mutta 
      kuitenkin sen verran löysästi, että lopussa minkään parametrin  
      kanssa ei joudu tappelemaan täysillä. 
   -> Tarkkaile tilannetta ”Console:n”, ”Prescription:n” ja  
      ”DVH Statistics:n” avulla. 
  -> Jo tässä vaiheessa on syytä keskeyttää laskenta, jos havaitsee, että 
      on syytä muuttaa parametreja, joita ei laskennan aikana voi mallailla. 
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  -> Kun laskenut ensimmäisen kierroksen, tarkastele ”Prescription” ja 
      Sensitivity” taulukoita. Ei kannata lähteä toiseen kierrokseen liian 
      tiukoilla vaatimuksilla. 
  
 - 2. Kierros (Monte Carlo): 
  -> Kannattaa laskettaa ensimmäisen kerran löysähköillä vaatimuksilla. 
      Tarkkaile tilannetta ”Prescription”:sta, mutta etenkin kiinnitä huomiota 
      ”DVH Statistics:n” PTV:n 95%:n annoksen osuuteen. Mallaile  
       parametreja niin, että algoritmi joutuu haasteisiin, mutta kuitenkin 
       sen verran löysästi, että koko PTV:n kattaisi 95% tavoite annoksesta 
       eikä lopussa minkään parametrin kanssa joudu tappelemaan täysillä. 
  -> Jos löysähköilläkin parametreilla oli vaikeuksia saavuttaa hyvää  
      annosjakaumaa, voi olla syytä muokata esimerkiksi Min.  
      MU/Segment” ja ”Min.Dose Rate”. Huomioi myös ”Console:sta”  
     segmenttien ja MU määrää sekä arvioitua hoitoaikaa (joka on ”beam-
     on”-aika). Tavoitteena voi pitää suuruusluokkia: Segmenttejä: 80-100, 
     MU: 700-900 ja hoitoaika: 180-280 sekuntia.(Hyvin kohdekohtaisia). 
   -> Jos näissä petrattavaa, on syytä muokata etenkin  
       arvoja: ”Min MU/Segment” ja ”Min.Dose Rate”, jolloin 
       koko laskentaprosessi on aloitettava alusta.  
  -> Kun annosjakauma on hyvä löysähköillä ”Prescription”:n kriteereillä, 
       segmentit, MU:t ja hoitoaika ovat ok, voi keskittyä mallailemaan 
     ”Prescription”:ia. Tällöin voi laskettaa vain 2.kierrosta, jossa samaan 
     aikaa optimoimalla haetaan parasta mahdollista annosjakaumaa. 
   -> Muista tallentaa välissä, sillä muokkaamalla jotakin 
       parametria, ja palauttamalla sen takaisin alkuperäiseen, 
       ei välttämättä tule uudestaan sama tulos Monte Carlo 
       algoritmilla lasketettaessa. 
 
Valmiin suunnitelma exportointi: 
  
 - Lähetä Linac 6:sen Xvi:lle suunnitelma CT-kuvan ja struktuurien kera. 
 - Lähetä suunnitelma Mosaiq:iin 
  -> Mosaiq:ssa jokainen suunnitelma omaan Course:en. 
  -> Luo myös kokonaisannoksen kirjautumiseksi summa sarake. 
 
Suunnitelmien annosjakaumien laadunvarmistus: 
 - Mittaa jokainen suunnitelma matrix:n ympärille kehitetyllä phantomilla. 
  -> Kerro mitattu annosjakauma kertoimilla: 
   -6 MV: 1,036 
   -10 MV: 1,045 
 - Mittaa myös yksi potilaan suunnitelma QA 0° - suunnitelmana. 
 
Hoito: 
 - Virtsarakon tyhjennys juuri ennen hoidon aloittamista. (Kemosädehoito: 1h     
    virtsarakon tyhjennys + 6dl vettä / kemosädehoidon nesteytys) 
 - CBCT-kuvaus Hexapod:lla potilaalle sopivalla CBCT-Presets asetuksella. 
              -> Hexapod pöytä asetettava nolla-kohtaansa. 
 - Auto-matching Grey-value algoritmilla, PTV:n kokoisella maskilla. 
              -> Tarkista Auto-matching:n tulos ja match:aa tarvittaessa manuaalisesti. 
- Valitaan CBCT-kuvan perusteella hoidettava kenttä. 
 - Hoidon jälkeen kuvaus potilaalle sopivalla CBCT-Presets asetuksella. 
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CBCT-kuvaus Xvi:lla: 
 - Potilaalle pyritään löytämään sopiva Xvi:n CBCT-Preset kuvauksiin. 
  -> Tarpeeksi hyvä kuvanlaatu mahdollisimman pienellä annoksella. 
 Work-flow: 
  1. Fraktio: 
   Kuvaus ennen: Prostate M10 Fast CCW 
   Kuvaus jälkeen: Rakko A CCW 7,5 – 11,7 mGy 
   
   
  Mikäli Prostate fast ei tarjoa tarpeeksi hyvää kuvanlaatua, on jatkossa 
  kuvattava Prostate –preset:illä. Tällöin on pohdittava kuinka usein ja 
  millä preset:llä hoidon jälkeisiä kuvauksia suoritetaan.  
 
  Mikäli Rakko A ei tarjoa tarpeeksi hyvää kuvanlaatua, päädytään  
  käyttämään jatkossa vain Prostate fast –preset:iä. 
 
  Mikäli Rakko A tarjoaa tarpeeksi hyvän kuvanlaadun: 
   
  2. Fraktio: 
   Kuvaus ennen: Rakko A CCW 7,5 – 11,7 mGy 
   Kuvaus jälkeen: Rakko B CCW 4,0 – 6,7 mGy 
   
  Mikäli Rakko B ei tarjoa tarpeeksi hyvää kuvanlaatua, päädytään  
  käyttämään jatkossa vain Rakko A –preset:iä. 
 
  Mikäli Rakko B tarjoaa tarpeeksi hyvän kuvanlaadun: 
   
  3. Fraktio: 
   Kuvaus ennen: Rakko B CCW 4,0 – 6,7 mGy 
   Kuvaus jälkeen: Rakko C CCW 3,0 – 4,5 mGy 
   
  Mikäli Rakko C ei tarjoa tarpeeksi hyvää kuvanlaatua, päädytään  
  käyttämään jatkossa vain Rakko B –preset:iä. 
 
  Mikäli Rakko C tarjoaa tarpeeksi hyvän kuvanlaadun, päädytään  
  käyttämään jatkossa vain Rakko C –preset:iä. 
 
Huomioi kuvauksien lopullisia Preset:ejä valitessa, että ennen hoitoa kuvattaessa on kuvan 
laadulla suurempi merkitys. Hoidon jälkeisiin ”off-line:na” tarkasteltaviin kuviin riittää heikompikin 
kuvan laatu.  
 
    Taulukko 1: Rakko potilaille käytettävien Xvi-presets:ien annoksia. (Mitattu CT-Thorax phantom:lla, r = 16 cm) 
 
Preset: Annos isosentrissä (mGy) Annos max. pinnassa (mGy) 
Prostate M10 20,5 35,7 
Prostate M10 Fast 11,2 18,5 
Rakko A 7,5 11,7 
Rakko B 4,0 6,7 
Rakko C 3,0 4,5 
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